Tegument Protein BNRF1 Regulation of Epstein-Barr Virus Genome Chromatinization During Early Infection by Tsai, Kevin
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2014
Tegument Protein BNRF1 Regulation of Epstein-
Barr Virus Genome Chromatinization During
Early Infection
Kevin Tsai
University of Pennsylvania, kevtsai@mail.med.upenn.edu
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, Molecular Biology Commons, and the Virology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1476
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Tsai, Kevin, "Tegument Protein BNRF1 Regulation of Epstein-Barr Virus Genome Chromatinization During Early Infection" (2014).
Publicly Accessible Penn Dissertations. 1476.
http://repository.upenn.edu/edissertations/1476
Tegument Protein BNRF1 Regulation of Epstein-Barr Virus Genome
Chromatinization During Early Infection
Abstract
Epstein-Barr virus (EBV) is a ubiquitously prevalent human herpesvirus whose persistent latent infection is
associated with many lymphomas. The prevalence of this virus can be attributed to its ability to establish a
persistent latent infection in host cells, during which only a small number of viral genes are expressed from a
highly regulated viral genome. However, it is not completely understood how EBV evades cellular antiviral
defenses and regulates chromatin assembly to establish latent infections. The EBV major tegument protein
BNRF1 was found to be required for the establishment of latent infections, and contains sequence homology
to cellular purine biosynthesis enzymes, yet neither the functional mechanism nor link to purine metabolism
is known. We have found that BNRF1 interacts with the cellular transcription co-repressor Daxx, and disrupts
the binding between Daxx and its interaction partner, the chromatin remodeler ATRX. By ectopically
complimenting BNRF1-null virus with mutant BNRF1, we found that the interaction with Daxx is essential
for BNRF1 to support viral gene expression and infection. Furthermore, knockdown studies show that Daxx
and ATRX are involved in the maintenance of viral chromatin during latency. With the Daxx-ATRX complex
recently found to function as a histone variant H3.3 chaperone, we found that BNRF1 forms a complex with
Daxx together with histones H3.3 and H4, suggesting potential modulation of a histone pre-deposition
complex. In support of this, we show that BNRF1 can increase the release of histone H3.3 into the cellular free
histone pool. We then show in primary infection of B lymphocytes that BNRF1-knockdown virus failed to
prevent Daxx-ATRX access to the viral chromatin. This results in enriched H3.3 and decreased active histone
H3K4me3 markers on the viral DNA, coinciding with deficient expression of viral latent genes. Our findings
demonstrate that EBV BNRF1, by interacting with Daxx and displacing ATRX, prevents repressive histone
variant H3.3 chromatin formation on viral DNA. Thus, BNRF1 is essential for the formation of viral
chromatin permissive for expressing viral latent genes. This is the first demonstration of a viral tegument
FGARAT-homology protein involved in the regulation of chromatin assembly. Most importantly, our findings
suggest that active manipulation of a histone pre-deposition complex could turn chromatin-based host
antiviral resistances into a mechanism of establishing viral latent chromatin.
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ABSTRACT 
TEGUMENT PROTEIN BNRF1 REGULATION OF EPSTEIN-BARR VIRUS GENOME 
CHROMATINIZATION DURING EARLY INFECTION 
Kevin Tsai 
Paul M. Lieberman, Ph.D. 
Epstein-Barr virus (EBV) is a ubiquitously prevalent human herpesvirus whose persistent 
latent infection is associated with many lymphomas. The prevalence of this virus can be 
attributed to its ability to establish a persistent latent infection in host cells, during which only 
a small number of viral genes are expressed from a highly regulated viral genome. However, 
it is not completely understood how EBV evades cellular antiviral defenses and regulates 
chromatin assembly to establish latent infections. The EBV major tegument protein BNRF1 
was found to be required for the establishment of latent infections, and contains sequence 
homology to cellular purine biosynthesis enzymes, yet neither the functional mechanism nor 
link to purine metabolism is known. We have found that BNRF1 interacts with the cellular 
transcription co-repressor Daxx, and disrupts the binding between Daxx and its interaction 
partner, the chromatin remodeler ATRX. By ectopically complimenting BNRF1-null virus with 
mutant BNRF1, we found that the interaction with Daxx is essential for BNRF1 to support 
viral gene expression and infection. Furthermore, knockdown studies show that Daxx and 
ATRX are involved in the maintenance of viral chromatin during latency. With the Daxx-
ATRX complex recently found to function as a histone variant H3.3 chaperone, we found 
that BNRF1 forms a complex with Daxx together with histones H3.3 and H4, suggesting 
potential modulation of a histone pre-deposition complex. In support of this, we show that 
BNRF1 can increase the release of histone H3.3 into the cellular free histone pool. We then 
show in primary infection of B lymphocytes that BNRF1-knockdown virus failed to prevent 
Daxx-ATRX access to the viral chromatin. This results in enriched H3.3 and decreased 
active histone H3K4me3 markers on the viral DNA, coinciding with deficient expression of 
viral latent genes. Our findings demonstrate that EBV BNRF1, by interacting with Daxx and 
vii	  
	  
displacing ATRX, prevents repressive histone variant H3.3 chromatin formation on viral DNA. 
Thus, BNRF1 is essential for the formation of viral chromatin permissive for expressing viral 
latent genes. This is the first demonstration of a viral tegument FGARAT-homology protein 
involved in the regulation of chromatin assembly. Most importantly, our findings suggest that 
active manipulation of a histone pre-deposition complex could turn chromatin-based host 
antiviral resistances into a mechanism of establishing viral latent chromatin. 
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1. The Purine Biosynthesis enzyme FGARAT-homology proteins in the 
gammaherpesvirus tegument  
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Tegument proteins constitute a prominent part of the herpesvirus viral particle, and are 
important for multiple steps of the viral infection life cycle. Located between the nuclear capsid 
and outer membrane in the viral particle, these proteins are pre-packaged and brought into the 
host cell during early infection. As a result, tegument proteins are well positioned to regulate the 
intracellular infection environment immediately after entry into the cytosol, effectively setting up 
shop in preparation for a productive viral infection. We and many others have recently noticed a 
family of tegument proteins that is conserved across all known members of the 
gammaherpesvirus subfamily.  This family contains conserved domains of sequence homology 
with the cellular purine biosynthesis enzyme phosphoribosylformylglycineamide amidotransferase 
(FGARAT). Members of this gene family include (but not limited to) the Epstein-Barr virus (EBV) 
BNRF1, Kaposi sarcoma herpesvirus (KSHV) ORF75, murine herpesvirus 68 (MHV68) ORF75c, 
and herpesvirus saimiri (HVS) ORF3, collectively referred to as viral FGARATs (vFGARATs). To 
date, efforts to elucidate the functions of vFGARATs have failed to reveal any enzymatic activity 
or interactions related to purine biosynthesis or metabolism in general. Instead, several recent 
reports have found that these tegument proteins disrupt different components of the 
nucleoplasmic structure PML nuclear body (PML-NB, also called ND10), which is involved in 
gene regulation and cellular innate antiviral resistances. Below, I will discuss the importance of 
tegument proteins in the herpesvirus life cycle, what we know about the FGARAT enzyme, the 
different ways that vFGARATs disrupt PML-NBs, examples of PML-NB disruption by non-
FGARAT herpesvirus proteins, and potential links between FGARAT-homology and the PML-
associated antiviral response. 
 
1.1 Tegument proteins in herpesviral biology 
As viruses are obligate parasites that propagate genetic information, the expression of viral 
genes in newly infected host cells is an early and essential step in the process of productive 
infection.  However, host cells pose multiple forms of intrinsic antiviral resistances that may 
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abrogate the early steps of viral infection even before viruses manage to express viral genes 
(Bieniasz, 2004). Herpesviruses package a collection of tegument proteins in the viral particle, 
which are released into the host cell right after cell entry. This early-stage presence allows 
tegument proteins to counteract host-cell antiviral resistances and enable productive infection to 
proceed. Tegument proteins can be classified into two groups, the inner tegument that is attached 
to the capsid and the outer tegument that can diffuse into the cytosol after cell entry. The inner 
tegument is generally associated with functions that mediate transport of the viral capsid to the 
cell nucleus. The functions of outer tegument proteins during early infection include inhibition of 
several branches of intrinsic immunity pathways, such as the host interferon response, 
inflammasome responses, and chromatin assembly-associated transcription repression. For 
example, EBV LF2 inhibits dimerization of the interferon regulator IRF7, in turn inhibiting type I 
interferon signaling (Wu et al., 2009); KSHV ORF45 also targets IRF7, preventing its 
phosphorylation and nuclear translocation, to block IRF7 transactivation of type I interferon genes 
(Zhu et al., 2002). KSHV tegument protein ORF63, interacts with the host detector of viral 
nucleotides NLRP1, preventing its association with active components of inflammasomes, 
resulting in less production of pyroptosis-associated cytokines IL-1beta and IL-18 (Gregory et al., 
2011). Furthermore, HSV-1 VP22 interacts with the cellular chromatin remodeler TAF-1, 
preventing TAF-1-associated nucleosome assembly (van Leeuwen et al., 2003). These examples 
demonstrate the complex and numerous cellular pathways targeted by viral tegument proteins 
and their functions during the early stages of viral infection.. 
 
1.2 Purine biosynthesis homology in the gammaherpesvirus tegument 
Sequence alignment tools such as NCBI BLAST revealed that the EBV major tegument 
protein BNRF1 contains several domains homologous with FGARAT. Many other mammalian 
viruses of the gammaherpesvirus subfamily encode BNRF1 homologues that are packaged in the 
tegument, and contain the FGARAT homologous domains conserved. Examples include the 
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ORF75 proteins of KSHV and MHV68. The fact that this FGARAT homology is conserved across 
all known gammaherpesviruses, but not alpha- or beta-herpesviruses, suggest that it is required 
for a part of the viral life cycle that is unique to gammaherpesviruses. 
FGARAT is an aminotransferase that hydrolyses ATP to power the transfer of an amino 
(NH2+) group from glutamine to formylglycineamide ribonucleotide (FGAR), forming the product 
formylglycineamidine ribonucleotide (FGAM) (Zhang et al., 2008). This is the fourth step in the 
ten-step de novo purine biosynthesis pathway, which synthesizes the purine precursor inosine 5'-
monophosphate (IMP) from phosphoribosyl pyrophosphate (PRPP). FGARAT is conserved 
across prokaryotes and eukaryotes, alternatively named PurL in bacteria. The crystal structure of 
the Salmonella typhimurium FGARAT (StPurL) has been solved (Anand et al., 2004). In this 
report, the authors described StPurL with a four-domain structure: 1) an N-terminal domain of 
unclear function, 2) a linker region, 3) the FGAM synthetase domain, and 4) a C-terminal 
glutaminase (GATase1) domain (Figure 3.3B). The FGAM synthetase domain has a pseudo-2-
fold symmetry structure of two aminoimidazole ribonucleotide synthetase (AIR_S/PurM) 
homology domains, with the first half containing the FGAM synthetase active site, and a 
catalytically inactive second half of similar structure that holds an ADP for unknown reasons. The 
C-terminal GATase1 domain removes the amine group off of glutamine and channels it to the 
FGAR substrate in the active site. 
A BLAST alignment of BNRF1 against Homo sapiens FGARAT showed 32% identity, with 
the homology most conserved on the C-terminal end (600aa to the end) of the BNRF1 protein. All 
viral vFGARAT are of similar size with human FGARAT and StPurL at approximately 1300aa. 
Aligning StPurL with the viral vFGARAT sequences revealed that the 702-954aa (BNRF1 
coordinates) of vFGARATs matches well with the FGAM synthetase subdomain; while 1040-
1306aa (BNRF1 coordinates) of vFGARATs matches with the C-terminal glutaminase (GATase1) 
domain. As the homology between BNRF1/ORF75 and FGARAT is spread across the whole 
protein with conservation of the overall domain structure, it is very likely that an early common 
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ancestor of gammaherpesviruses obtained a copy of the host FGARAT gene. The 32% identity 
suggests that vFGARATs may have divergently evolved away from FGARAT, yet retained the 
overall protein structure.  
Ling et al. previously reported that the conserved ATP and glutamine -binding motifs of 
FGARAT do not seem to be conserved in MHV68 ORF75c (Ling et al., 2008). Our alignments of 
EBV BNRF1 with human FGARAT also found that the one presumptive ATP interaction site and 
three presumptive glutamine amide transfer domains on human FGARAT (as reported by 
(Patterson et al., 1999)) are not well conserved on BNRF1, with the ATP interaction site 
seemingly deleted from vFGARATs. However, we did find high conservation between the 
vFGARATs and the second PurM domain of StPurL (Figure 1.1). Specifically, all of the conserved 
residues of StPurL that were reported (Anand et al., 2004) to form hydrogen bonds with ADP in 
the auxiliary ADP site (K649, E718, N722, D884, D887) can be found on BNRF1 (K627, E729, 
N733, D883, D886), while most of the magnesium ion ligands that help stabilize ADP are also 
conserved on BNRF1. These ADP interacting residues are conserved in all vFGARATs that we 
tested. Meanwhile, in the glutaminase domain, only two (G1093, Q1139 of StPurL) of the five 
glutamine-interacting residues are conserved on BNRF1 (G1089, Q1137); these G and Qs could 
also be found in all vFGARATs except HVS ORF3. This leads to the intriguing conclusion that 
vFGARATs have lost the known FGARAT catalytic sites in the FGAM synthetase and GATase1 
domains, yet are most conserved in an ADP-holding site of unknown function. Also, the Daxx-
interaction domain that we have found on BNRF1 (360-600aa, Figure 2.3) (Tsai et al., 2011) 
spatially maps to the first PurM domain of StPurL where the FGAR synthetase active site should 
be. We think this may suggest that the substrate holding domain that holds FGAR has divergently 
evolved to hold Daxx instead, and begs the yet unanswered question of why does BNRF1 need 
to hold an ADP molecule next to Daxx. 
The partially conserved homology raises the question whether these viral tegument proteins 
have a related, but altered “FGARAT-like” enzymatic activity.  Some possibilities include ATPase, 
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phosphate transfer, amidation or deamidation activity. It is also possible that FGARAT homology 
tegument proteins sense or modulate intracellular levels of nucleotides and related metabolites.  
Intracellular nucleotide levels are clearly important for viral infections. For HIV infection, the 
intrinsic restriction factor SAMHD1 hydrolyses dNTP to decrease the intracellular nucleotide pool 
available for viral replication (Ayinde et al., 2012). Both HSV-1 and EBV encode viral Thymidine 
Kinases (TK) to ensure the supply of sufficient dNTPs during lytic infection (Chen et al., 1979; de 
Turenne-Tessier et al., 1986). These examples highlight the importance of dNTPs during lytic 
replication. However, gammaherpesvirus vFGARATs may not be required for lytic cycle DNA 
replication since BNRF1 is expressed as a late gene that could not be detected prior to DNA 
replication (Alfieri et al., 1991). Thus, the role of vFGARATs in regulating or sensing nucleotide 
levels is not clear. So far there are no reports of enzymatic activity associated with vFGARATs, 
nor any nucleotide metabolism associated functions found. As discussed below, we have 
attempted to test BNRF1 for ATPase activity; however, we could not confirm if the ATPase 
activity we detected was that of BNRF1 itself or a co-purifying cellular contaminant (Figure 3.3D-
H). 
 
1.3 PML-NBs and antiviral resistances 
Recent studies of the vFGARATs reveal a common function of disrupting PML nuclear 
bodies (PML-NBs, also named ND10), a cell nuclear structure that has no known link with purine 
metabolism. PML-NBs are protein aggregate structures in the nucleus (Ascoli and Maul, 1991), 
where the pro-myelocytic leukaemia (PML) protein forms a cage-like shell surrounding associated 
components (Dellaire et al., 2009; Luciani et al., 2006), such as (but not limited to) Sp100, Daxx, 
ATRX, and HP1. PML-NBs are associated with multiple cellular functions including gene 
expression, telomere regulation, chromatin remodeling, apoptosis, post-translational protein 
modifications, and antiviral resistance. The many functions of PML-NBs has been extensively 
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reviewed (Eskiw and Bazett-Jones, 2002; Lallemand-Breitenbach and de Thé, 2010; Negorev 
and Maul, 2001). 
The association of PML-NBs with intrinsic antiviral immunity is demonstrated through its 
response to viral infections and virus-induced disruption of these nuclear bodies. Interferons, 
which are major regulators of antiviral responses, can directly induce the increase of the size and 
abundance of PML-NBs (Chelbi-Alix et al., 1995; Lavau et al., 1995). Both type I and type II 
interferons can directly increase the gene expression of the major components of PML-NBs, PML 
(Stadler et al., 1995) and Sp100 (Guldner et al., 1992) This up-regulation is specifically through 
interferon stimulated response elements (ISRE) and interferon-gamma activation sites (GAS) that 
are located in the promoters of both PML (Stadler et al., 1995) and Sp100 (Grotzinger et al., 1996) 
genes. PML-NBs are the nuclear localization site of many herpes viruses immediately after 
nuclear entry, such as with Herpes Simplex virus (HSV-1) (Ishov and Maul, 1996) and Human 
Cytomegalovirus (HCMV) (Korioth et al., 1996). This suggests a model where PML-NBs act as 
the rendezvous where interferon-inducible host antiviral resistance effectors and viral genomes 
meet. Direct evidence of PML-NBs involvement in antiviral resistance are provided through 
overexpression and knockdown studies: PML over-expression has an inhibitory effect on both 
vesicular stomatitis virus (VSV) and influenza virus gene expression and replication (Chelbi-Alix 
et al., 1998). Knockdown of PML and Sp100 may accelerate mutant HSV-1 that are deficient in 
PML disruption (Everett et al., 2008); while PML and Daxx knockdown results in an increase in 
HCMV replication (Tavalai et al., 2008). 
 
1.4 Known functions of viral FGARAT-homology tegument proteins 
 The murine herpesvirus MHV68 (also named gamma-herpesvirus 68) belongs to the 
rhadinovirus genus of gammaherpesviruses, along with the squirrel monkey virus HVS and 
human virus KSHV. MHV68 encodes three FGARAT homologues, ORF75a, ORF75b, and 
ORF75c. A high throughput screen in fibroblasts found that only the ORF75c is essential for viral 
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infection in fibroblasts (Song et al., 2005). In a more focused study, ORF75c was found to induce 
PML degradation in fibroblasts, while leaving Daxx intact (Ling et al., 2008). PML degradation is 
likely due to ubiquitin-E3 ligase activity of ORF75c (Sewatanon and Ling, 2013). We have tested 
the ORF75a/b/c constructs made by Ling et al. and observed that none of the ORF75 proteins 
could interact or degrade Daxx in 293T cells (unpublished data). This protein may be 
multifunctional as ORF75c knockout virus doesn’t just fail to induce PML degradation but also 
showed reduced transport of viral capsids into the nucleus (Gaspar et al., 2008). Intriguingly, a 
recent report found another MHV68 gene ORF61, a ribonucleotide reductase (RNR) large subunit 
homologue that reorganizes PML-NBs into track-like structures (Sewatanon and Ling, 2014). 
The squirrel monkey rhadinovirus HVS, encodes two vFGARATs: ORF3, and ORF75 
(Albrecht et al., 1992). One report looked into the function of these two proteins in viral infection 
of both human and rhesus macaque fibroblasts. ORF3, but not ORF75, was found to specifically 
induce proteosomal degradation of Sp100, while sparing PML and Daxx (Full et al., 2012). 
Knockdown of Sp100 could partially rescue ORF3-null virus infection, however PML knockdown 
resulted in a stronger rescue. This suggests that while Sp100 can repress viral infection, the 
structural support by PML formation of nuclear bodies may aid in focusing Sp100 onto viral DNA.  
The human rhadinovirus KSHV encodes one vFGARAT homologue, ORF75. We have 
probed KSHV ORF75 for interaction with Daxx in 293T cells but found no interaction in our 
immunoprecipitation (unpublished data). However, a recent study showed that stable Daxx-
binding seems to be one of the few things that ORF75 doesn't do (Full et al., 2014). This study 
showed that PML and Sp100, but not ATRX knockdown, resulted in increased KSHV infection in 
fibroblasts. That ATRX doesn't restrict infection could be explained by the observation that 
ORF75 can induce degradation of ATRX, while also inducing dispersion of Daxx, PML, and 
Sp100 away from nuclear bodies. Degradation of ATRX can be induced by tegument delivered 
ORF75 as de novo viral gene expression was not needed. Yet, confusingly, dispersion of PML 
and Sp100 was only observed with transfected ORF75, but not during viral infection. Absence of 
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PML and Sp100 dispersion during early infection was confirmed in a separate study, which also 
showed that PML and Sp100 mRNA expression was increased upon primary infection (Günther 
et al., 2014). KSHV ORF75 may also have different functions in different stages of viral infection, 
as it was found in a high-throughput screen as one of the KSHV gene that could activate the 
expression of the cellular transcription factor NF-κB, which is crucial for the progression of KSHV-
associated cancers (Konrad et al., 2009). Upon ORF75 knockdown, NF-κB levels were down 
regulated in KSHV-latently infected 293 cells. The study by Full et al. also found that ORF75 
knockout virus could not express lytic gene upon induction, and thus failed to replicate. These 
recent studies on KSHV ORF75 suggest that the functions of vFGARAT tegument proteins might 
not be restricted to the early infection phase if they are expressed during latency; rather, at least 
in the case of KSHV, vFGARATs may support all stages of the virus life cycle, including pre-latent, 
latency, and lytic replication phases. 
In the case of EBV, a human gammaherpesvirus of the lymphocryptovirus genus, only a 
single vFGARAT, BNRF1, exists. In a study utilizing BNRF1-deleted virus (△BNRF1), BNRF1 
was found to be essential during early infection of B lymphocytes for viral gene expression and 
induction of B cell proliferation, while not needed for lytic replication (Feederle et al., 2006). Of 
note, this study found that △BNRF1 virus showed no defect in cell entry up to the endosomal 
compartment yet failed to express the viral gene EBNA2, suggesting that BNRF1 must be 
important in a step between cell entry and viral gene expression. This has been frequently 
misinterpreted to suggest that BNRF1 is required for nuclear entry; a misunderstanding that 
contradicts with the author's note that there was no observation of viral capsid accumulating on 
the nuclear periphery. In our studies, we have noticed that BNRF1-null virus infection consistently 
resulted in a two-fold lower viral DNA copy number in infected cells when compared with BNRF1-
intact virus (unpublished data), and viral DNA could still be detected in infected B lymphocyte 
nuclei by fluorescence in situ hybridization (FISH, Figure 3.7). While this does not rule out 
BNRF1-involvement in nuclear entry, BNRF1-null virus can still enter the nucleus at a slightly 
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lower efficiency. We have found that a prominent function of BNRF1 is its interaction with Daxx at 
the PML-NBs, and dispersion of ATRX away from the PML nuclear bodies (Tsai et al., 2011). 
Unlike rhadinovirus vFGARATs, we observed no BNRF1-induced degradation of any PML-
components. The complex of Daxx and ATRX was recently reported to form a histone variant 
H3.3 chaperone (Drane et al., 2010; Lewis et al., 2010). In a histone chaperone-like fashion, we 
found that BNRF1 can increase the free histone H3.3 pool in the nucleus. By displacing ATRX 
and forming an alternative complex of BNRF1/Daxx/H3.3/H4, tegument-delivered BNRF1 can 
decrease Daxx, ATRX, and H3.3 loading on viral genomes (see chapter 3). This ensures the 
presence of permissive chromatin on the first activated viral promoter Wp, and permits viral gene 
expression. In this study, we provide evidence that BNRF1 disruption of PML-NB antiviral 
repression involves the modulation of Daxx-H3.3 histone chaperone function and regulation of 
viral chromatinization. 
 
1.5 Non-vFGARAT examples of viral disruption of PML-NBs 
Herpesviral disruption of PML-NBs are best demonstrated with alpha- and beta-
herpesviruses, that do not encode vFGARAT homologues. HSV-1 protein ICP0 is an immediate 
early gene that is also found in small amounts in the tegument (Loret and Lippé, 2012; Loret et al., 
2008). ICP0 is required to activate viral early gene expression during lytic activation and 
reactivation (reviewed in (Everett, 2000; Hagglund and Roizman, 2004)). ICP0 disrupts PML and 
Sp100 from localizing to PML-NBs (Maul and Everett, 1994; Maul et al., 1993) through inducing 
degradation of PML and certain isoforms of Sp100 (Chelbi-Alix and de The, 1999). ICP0-null 
mutant virus was shown to be deficient in viral gene expression while shRNA-mediated 
knockdown of PML and Sp100 resulted in a partial rescue of viral gene expression (Everett et al., 
2008), suggesting that the gene activation activity of ICP0 may be though its disruption of PML-
NBs. 
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HCMV, on the other hand, utilizes the tegument protein pp71 to inactivate PML-associated 
repression and stimulate viral gene expression (Penkert and Kalejta, 2012). pp71 was found to 
target Daxx, a cellular transcription co-repressor associated with PML-NBs. Upon primary 
infection of permissive cell types, pp71 was found to localize to PML-NBs (Ishov et al., 2002), 
bind Daxx (Hofmann et al., 2002), induce Daxx degradation (Hwang and Kalejta, 2007), and 
disperse the Daxx-interaction partner ATRX, away from PML-NBs (Lukashchuk et al., 2008), 
breaking apart the Daxx-ATRX chromatin remodeling complex. The impact of Daxx on HCMV 
infection was shown through the observation that siRNA-mediated Daxx knockdown resulted in 
increased active histone markers (presence of H4 acetylation, absence of H3K9 di-methylation) 
and immediate early (IE) gene expression; while Daxx over-expressing cells are refractory to 
HCMV IE gene expression (Woodhall et al., 2006), emphasizing the role of Daxx in the 
repression of viral gene expression.  
 
1.6 Possible links between FGARAT-homology and PML-associated antiviral 
resistance 
A lot has been learned of vFGARAT tegument proteins in the recent few years, yet these 
new findings have yielded more surprises than the FGARAT homology could have ever lead us to 
predict. While our efforts of exploring a possible enzymatic activity of vFGARATs continue, the 
striking common theme with vFGARATs is that they all target different components of PML-NBs. 
We could currently speculate that either 1) PML-NB associated anti-viral resistance involved 
FGARAT-associated activities such as nucleotide metabolism; or 2) an amine transferase 
enzyme that was copied in a common ancestor has mutated and gained a new function. The two 
possibilities are not necessarily mutually exclusive, and the former could be the reason for the 
convergent evolution in the later. The first possibility is an interesting one, as the two MHV68 
genes, vFGARAT ORF75, and ribonucleotide reductase ORF61; both target PML for degradation, 
and both are homologous with enzymes involved in nucleotide metabolism. Given that 
vFGARATs are only found in gammaherpesviruses, but not alpha or beta- herpesvirus, we could 
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also hypothesize that this link between nucleotide metabolism and PML-mediated resistance 
might involve something specific to lymphocytes, as this cell type preference is one of the main 
differences between gammaherpesviruses and the other herpesviruses. 
Comparing between the vFGARATs of rhadinoviruses (KSHV, MHV68, and HVS) and 
lymphocryptovirus (EBV), there is also a difference in how they disrupt PML-NBs. The 
vFGARATs of rhadinoviruses all induced degradation of at least one PML component; however 
we have found no evidence of lymphocryptovirus vFGARATs (EBV BNRF1) inducing any protein 
degradation. It is possible that we just haven't found the degradation target, as EBV BNRF1 is the 
only lymphocryptovirus vFGARAT studied so far. All rhadinoviruses degradation studies were 
done in either fibroblasts or endothelial cells (in the case of KSHV ORF75); while we did not 
observe any hint of degradation induction in 293T, HeLa cells, or B lymphocytes. It would be 
interesting to test if any of the vFGARATs would have differing degradation functionality in 
different cell types, specifically if rhadinovirus vFGARATs could still degrade PML components in 
lymphoid or other cell types. This would not be without precedent, as in the case of HCMV, the 
sub-cellular localization of pp71 could control the choice between lytic and latent replication (as 
reviewed (Penkert and Kalejta, 2011)) in a cell type dependent manner. Pp71 may enter the 
nucleus and degrade Daxx upon infection of lytic permissive fibroblasts; however, in CD34+ 
hematopoietic progenitor cells (HPCs), HCMV pp71 remains in the cytosol, allowing Daxx to 
repress viral gene expression and establish viral latency (Saffert et al., 2010). This parallels the 
HSV-1 tegument protein VP16, which is left in the cytosol upon infection of neurons and not able 
to activate ICP0 expression and PML disruption, thus resulting in latency (as discussed in 
(Penkert and Kalejta, 2011)). As EBV preferentially undergoes lytic gene expression in epithelial 
cells but latent gene expression in lymphocytes, it would be interesting to test if BNRF1 may act 
as a cell type dependent lytic/latent switch. 
There remains lots to be learned about vFGARATs, with the primary questions still 
unanswered: What do viral copies of FGARAT contribute to the viral life cycle? Do vFGARATs 
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still retain enzymatic activity, be it ATPase, amido transfer, or glutaminase activities? And what 
are the substrates? Furthermore, vFGARATs are all large proteins, and there might be more 
functions yet to be found. Viral mimicry of host genes are fascinating and not uncommon (Elde 
and Malik, 2009). When mimicry of a certain gene is conserved across multiple viruses and 
consistently associated with functions seemingly unrelated to the mimicked host gene, it is very 
likely that these mimics are pointing us to important cell biology that is yet to be elucidated. 
	    
14	  
	  
1.7 Figures 
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Figure 1.1 Sequence alignment of vFGARATs to human FGARAT and StPurL 
Amino acid alignment of known viral FGARAT-homologues to human FGARAT and 
Salmonella typhimurium PurL (StPurL). Alignment done with Clustal Omega program (ver. 1.2.1) 
hosted at The European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
(Sievers et al., 2011). Completely matched residues denoted by a star. Putative ATPase and 
Glutamine binding domains as identified in (Patterson et al., 1999) are marked with an underline. 
Residues that form hydrogen bonds with ADP at the auxiliary ADP site as listed on StPurL 
(Anand et al., 2004) are marked in green; while the Glutamine interacting residues of StPurL 
GATase1 domain are marked in red. 
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2. EBV Tegument Protein BNRF1 Disrupts DAXX-ATRX to Activate Viral Early 
Gene Transcription 
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2.1 Abstract 
Productive infection by herpesviruses involve the disabling of host-cell intrinsic defenses by 
viral encoded tegument proteins. Epstein-Barr Virus (EBV) typically establishes a non-productive, 
latent infection and it remains unclear how it confronts the host-cell intrinsic defenses that restrict 
viral gene expression. Here, we show that the EBV major tegument protein BNRF1 targets host-
cell intrinsic defense proteins and promotes viral early gene activation. Specifically, we 
demonstrate that BNRF1 interacts with the host nuclear protein Daxx at PML nuclear bodies 
(PML-NBs) and disrupts the formation of the Daxx-ATRX chromatin remodeling complex. We 
mapped the Daxx interaction domain on BNRF1, and show that this domain is important for 
supporting EBV primary infection. Through reverse transcription PCR and infection assays, we 
show that BNRF1 supports viral gene expression upon early infection, and that this function is 
dependent on the Daxx-interaction domain. Lastly, we show that knockdown of Daxx and ATRX 
induces reactivation of EBV from latently infected lymphoblastoid cell lines (LCLs), suggesting 
that Daxx and ATRX play a role in the regulation of viral chromatin. Taken together, our data 
demonstrate an important role of BNRF1 in supporting EBV early infection by interacting with 
Daxx and ATRX; and suggest that tegument disruption of PML-NB-associated antiviral 
resistances is a universal requirement for herpesvirus infection in the nucleus. 
 
2.2 Author Summary 
Persistent infection by Epstein-Barr virus (EBV) is associated with a variety of diseases, 
including lymphoid and epithelial tumors. Despite a wealth of information on the mechanism of 
viral persistence, relatively little is known about the early steps of EBV infection and viral gene 
activation. Host cells actively mount resistances against viral infection, which viruses need to 
overcome to invade the cell. We have found that among the proteins packaged in the EBV viral 
particle, BNRF1 plays an important role of counteracting cellular defenses. We show that EBV 
protein BNRF1 binds to the cellular protein Daxx and disassembles the Daxx-ATRX complex, 
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where both Daxx and ATRX are cellular proteins known to inhibit viral gene expression. We also 
confirm that BNRF1 can promote expression of early viral genes, and that Daxx-binding by 
BNRF1 is required for this function. Finally, we demonstrate that Daxx and ATRX repress viral 
gene expression during latency. We conclude that BNRF1 disassembles cellular antiviral defense 
machinery to promote expression of viral genes in the host cell. 
 
2.3 Introduction 
Epstein-Barr virus (EBV) is a member of the human gammaherpesvirus subfamily that 
infects over 90% of the global adult population (Cohen, 2000; Rickinson and Kieff, 2007). EBV 
preferentially establishes latent infection in B-lymphocytes but can also infect epithelial cells 
(Young and Rickinson, 2004). EBV primary infection is one of the main causes of infectious 
mononucleosis (IM); while EBV latent infection is associated with multiple malignancies such as 
nasopharyngeal carcinoma, Burkitt's lymphoma, and Hodgkin's lymphoma (Young and Rickinson, 
2004). Furthermore, EBV is responsible for the majority of lymphoproliferative diseases 
associated with AIDS and immunosuppression following organ transplant (Gottschalk et al., 2005). 
Like all herpesviruses, EBV exists in a dynamic balance between productive and latent infection. 
The factors that regulate the fate decisions for lytic reactivation from latency have been 
investigated in some detail, but relatively little is known about the fate regulation during the 
earliest stages of primary infection. 
Upon entry into the nuclear compartment, herpesvirus DNA genomes must confront several 
intrinsic anti-viral resistances that restrict viral gene expression and replication. One prominent 
nuclear structure involved in antiviral resistances is the PML nuclear body (PML-NB), also 
referred to as nuclear domain 10 (ND10). PML-NBs are nucleoplasmic protein aggregates mainly 
consisting of (but not limited to) the components PML, Sp100, Daxx, and ATRX (Bernardi and 
Pandolfi, 2007; Everett and Chelbi-Alix, 2007). The size and abundance of PML-NB is interferon 
inducible (Chelbi-Alix et al., 1995; Grotzinger et al., 1996; Lavau et al., 1995), and over-
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expression of the PML protein represses viral infection (Chelbi-Alix et al., 1998). PML-NB is the 
nuclear localization site of many DNA viruses, including Herpes Simplex virus (HSV-1), Human 
Cytomegalovirus (HCMV) and Adenovirus (Ad5) (Ishov and Maul, 1996; Korioth et al., 1996). 
These viruses then modify the morphology and/or protein composition of PML-NBs shortly after 
infection (Hensel et al., 1996; Ishov and Maul, 1996). The mechanism of PML-NB-mediated 
antiviral repression is not clearly determined. PML, Sp100, and Daxx are all associated with 
transcription repression, and this function may act on viral genomes (Zhong et al., 2000). Daxx 
can act as a transcription co-repressor of many cellular transcription factors (Emelyanov et al., 
2002; Lehembre et al., 2001; Li et al., 2000b; Michaelson and Leder, 2003), and forms repressive 
transcription complexes with histone deacetylases (HDACs) (Hollenbach et al., 2002; Li et al., 
2000a) and DNA methyltransferase I (DNMT I) (Michaelson et al., 1999; Muromoto et al., 2004). 
Daxx has been shown to induce heterochromatin markers on the HCMV genome and repress 
viral gene expression in a HDAC dependent manor (Saffert and Kalejta, 2006; Woodhall et al., 
2006). Daxx also forms a chromatin-remodeling complex with ATRX (Xue et al., 2003) and both 
can form a repression complex at heterochromatin (Ishov et al., 2004). Furthermore, RNA 
interference (RNAi) studies have shown that knockdown of Daxx or ATRX can result in a higher 
infection level of HCMV (Cantrell and Bresnahan, 2006; Lukashchuk et al., 2008; Tavalai et al., 
2008) and also relieve the infection defect of mutant HSV deficient in disrupting PML-NB 
(Lukashchuk and Everett, 2010). 
Herpesviruses confront intrinsic anti-viral resistances immediately upon entering the host 
cell nucleus, and therefore must counteract these resistances at the earliest possible time points 
to initiate viral gene expression. Herpesvirus tegument proteins, which are pre-packaged and 
delivered with the infectious virion, are strategically positioned to counteract the intrinsic anti-viral 
defenses and support the early steps of infection (Smibert et al., 1994). Both alpha- and beta- 
herpesviruses encode tegument proteins that regulate early events during lytic replication, 
including the disruption of the PML-NBs. HSV-1 immediate early gene ICP0, disrupts PML-NB 
structure by degrading the core component PML (Boutell et al., 2002; Everett et al., 1998; Maul et 
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al., 1993) and eliminating SUMO-modified Sp100 (Everett et al., 2006); while HCMV tegument 
protein pp71 displaces ATRX and subsequently degrades Daxx (Lukashchuk et al., 2008; Saffert 
and Kalejta, 2006). Both ICP0-deficient HSV-1 and pp71-deficient HCMV mutants are deficient in 
infection, where viral gene expression is shutdown, resulting in a dormant viral genome (Cantrell 
and Bresnahan, 2006; Preston and Nicholl, 1997; Stow and Stow, 1989). Interestingly, it has 
been reported that disruption of PML-NB by ICP0 is mediated by de novo synthesized ICP0, 
instead of tegument delivered ICP0 protein, suggesting that this event is coordinated with early 
viral gene activation or, perhaps, reactivation from latent infection (Maul et al., 1993). We have 
previously shown that EBV genomes localize to and then disrupt PML-NB during lytic replication; 
while latent EBV episomes are segregated away from PML-NBs during latency (Bell et al., 2000). 
EBV regulatory proteins, including the lytic cycle immediate early gene Zta (also referred to as 
BZLF1, ZEBRA, and Z), and latency associated EBNA1 and EBNA-LP, have been implicated in 
PML-NB interactions (Adamson and Kenney, 2001; Ling et al., 2005; Sivachandran et al., 2010). 
However, it remains unclear if PML-NBs regulate early events associated with viral gene 
expression upon EBV nuclear entry, and if an EBV tegument protein modulates this intrinsic 
defense. 
The EBV major tegument protein BNRF1 is one of the most abundant tegument proteins in 
the virion (Johannsen et al., 2004) and is essential for the establishment of viral latent infection 
(Feederle et al., 2006), yet its function is largely unknown. BNRF1 homologues are present in all 
gammaherpesviruses but absent in the alpha- and beta- herpesvirus subfamilies. All BNRF1 
orthologues share regions homologous to the cellular enzymes 
Phosphoribosylformylglycineamide Amidotransferase (FGARAT) and Aminoimidazole 
ribonucleotide (AIR) synthetase, ATP-dependent enzymes in the 4th and 5th steps of the purine 
de novo biosynthesis pathway. However, no enzymatic activity has been found in any BNRF1 
orthologues. In a knockout study, transfected BNRF1-deficient EBV genomes can reactivate from 
latency, produce morphologically normal virions, and the progeny can enter cells with little 
observed defects (Feederle et al., 2006). Yet, upon infection of B cells the mutant virus showed a 
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20-fold lower expression of a viral latency associated gene EBNA2 and failed to induce B cell 
transformation (Feederle et al., 2006). This suggests an important role of BNRF1 in supporting 
early infection. Furthermore, the BNRF1 orthologue encoded by murine herpes virus 68 (MHV68), 
tegument protein ORF75c, induces PML degradation and is essential for initiation of viral gene 
expression (Gaspar et al., 2008; Ling et al., 2008). 
 
Here, we demonstrate that EBV BNRF1 is a novel PML-NB-interacting viral protein, and that 
this interaction is important for supporting EBV primary infection. We first show that Daxx is a 
primary cellular interaction partner of BNRF1. BNRF1 co-localizes with Daxx at PML-NB foci 
while disrupting the Daxx-ATRX complex. Furthermore, we identify a novel Daxx interaction 
domain on BNRF1. This domain is essential for BNRF1 to interact with Daxx, localize to PML-NB, 
and displace ATRX from Daxx. We then show that BNRF1 supports EBV primary infection and 
promotes the expression of viral genes soon after viral genomes enter the cell, and that the Daxx 
interaction domain contributes to these functions. Lastly, we show that knockdown of either Daxx 
or ATRX results in disruption of viral latency, suggesting that Daxx and ATRX play a role in the 
restriction of viral gene expression. Our study suggests that EBV tegument protein BNRF1 
disassemble the Daxx-ATRX antiviral resistance complex to enable viral gene expression after 
cell invasion, and likely regulate the chromatin organization for the establishment of latent 
infection. 
2.4 BNRF1 interacts with cellular protein Daxx 
To characterize the biological properties of the EBV major tegument protein BNRF1, we took 
a proteomic approach to screen for potential cellular interaction partners. BNRF1 was cloned into 
a 3x FLAG tag expression vector under the control of a CMV promoter. 293T cells were then 
stably transfected with either FLAG-vector or FLAG-tagged BNRF1. Nuclear extracts from stable 
cell lines were subject to immunopurification (IP) with a FLAG antibody, and then analyzed by 
SDS-PAGE (Figure 2.1A). Bands unique to the BNRF1 lane (B) were cut out and analyzed by 
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liquid chromatography-tandem mass spectrometry (LC/MS/MS). The major identified species was 
BNRF1, but substoichiometric proteins enriched in the BNRF1 IP were also identified, including 
Daxx, nucleophosmin (NPM1), and PARP1 (Figure 2.1C). We subsequently confirmed in BNRF1 
transiently transfected 293T cells that Daxx co-precipitates with BNRF1 (Figure 2.1B) by both 
FLAG pull-down and the Daxx reverse pull-down, indicating a stable in vivo interaction between 
BNRF1 and Daxx. Neither PARP1 nor NPM1 interaction with BNRF1 could be validated by 
subsequent co-IPs (data not shown), we therefore focused our efforts on characterizing the 
interaction with Daxx. 
2.5 BNRF1 utilizes a novel Daxx interaction domain 
To further characterize the interaction between BNRF1 and Daxx, we introduced serial 
deletions on the FLAG-BNRF1 expression plasmid. We first made five deletion constructs of 
BNRF1, sequentially deleting regions coding for 300 amino acids (Figure 2.2A, constructs d1 
through d5). We then performed IPs with either control IgG, αFLAG, or αDaxx on lysates of cells 
transfected with the BNRF1 deletion constructs. Daxx co-precipitated in the FLAG IP for all of the 
BNRF1 mutants with the exception of the BNRF1 300–600 aa deletion mutant (d2) (Figure 2.2B, 
middle panels). Similarly, all of the FLAG-BNRF1 mutants, with the exception of d2, co-
precipitated with Daxx IP (Figure 2.2B, right panels). Since d2 was expressed and recovered by 
FLAG IP to similar levels as other BNRF1 mutants capable of interacting with Daxx, we conclude 
that a putative Daxx-interaction domain is located in the region between 300-600aa of BNRF1. 
We then further made six serial deletions of 60 amino acids in the 300–600 aa region 
(Figure 2.3A, constructs d21 through d26) to narrow down the suspected Daxx-interaction domain 
to a smaller region. After a subsequent round of IP pull-downs, we found that all BNRF1 deletions, 
with the exception of d21, were defective in binding Daxx (Figure 2.3B), suggesting that the 360–
600 aa region of BNRF1 is responsible for interaction with Daxx. To determine if this region was 
sufficient for interaction with Daxx, we expressed only the 300–600 aa region in the FLAG-
expression vector (Figure 2.3A, construct DID) and performed IP pull-downs. We found that this 
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region bound Daxx as efficiently as WT-BNRF1, in both FLAG IP and in the reverse IP with anti-
Daxx antibody (Figure 2.3C). Notably, we failed to find sequence homology of this Daxx 
interaction domain with any known protein motif, and this domain is also distinct from the 
FGARAT and AIR synthetase homology regions. These findings suggests that BNRF1 utilizes a 
previously unknown motif to bind Daxx, and that the Daxx interaction domain (300–600 aa) may 
contain a complex protein fold sensitive to smaller truncation deletions. 
2.6 BNRF1 disrupts the Daxx-ATRX chromatin remodeling complex 
Daxx forms a chromatin remodeling complex with ATRX (Xue et al., 2003) and ATRX has 
been implicated in the transcriptional repression of both HSV-1 and HCMV during the early steps 
of infection (Lukashchuk et al., 2008). Moreover, both HSV-1 and HCMV utilize viral encoded 
proteins that disrupt the interaction between Daxx and ATRX (Lukashchuk and Everett, 2010; 
Lukashchuk et al., 2008). To determine if BNRF1 also disrupted the interaction between Daxx 
and ATRX, we assayed the effect of WT and mutant BNRF1 proteins on the co-IP of Daxx with 
ATRX. We observed that WT BNRF1 disrupted the interaction between Daxx and ATRX (Figure 
2.3C, 2nd panel from top, right). However, deletion mutants d22 and d26, which fail to interact 
with Daxx, did not disrupt ATRX binding in Daxx IP assays (Figure 2.3C, 2nd panel from top, 
right). Interestingly, the Daxx interaction domain by itself (DID), which binds Daxx efficiently, 
could only partially disrupt ATRX binding. This suggests that Daxx binding by BNRF1 is 
necessary, but not sufficient for the disruption of ATRX with Daxx. We also found no evidence 
that BNRF1 co-IPs with PML (Figure 2.3C, 3rd panel from top). 
To determine whether any other domains of BNRF1 contribute to the disruption of ATRX 
from Daxx, we assayed FLAG-BNRF1 IPs for ATRX binding using the set of larger BNRF1 
deletions examined in Figure 2.2 (Figure 2.3D). We found that WT BNRF1 did not co-IP with 
ATRX, although it efficiently pulled down Daxx. The BNRF1 d2 mutant failed to pull down Daxx or 
ATRX, as expected. In contrast, the BNRF1 d3 and d4 mutants, which disrupts most of the 
FGARAT and AIR synthetase homology regions, efficiently pulled down both ATRX and Daxx. 
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The d1 and d5 truncations, which lie outside of the FGARAT and AIR synthase homology regions, 
pulled down only Daxx but not ATRX, suggesting it efficiently disrupted the ATRX-Daxx 
interaction similar to WT. These data suggest that the FGARAT and AIR synthetase homology 
regions of BNRF1 may contribute to the disruption of ATRX-Daxx complex. 
 
2.7 BNRF1 co-localizes with Daxx to PML nuclear bodies and disperses ATRX 
from nuclear bodies, in a Daxx interaction domain-dependent manner 
Daxx is a prominent component of PML nuclear bodies (Lindsay et al., 2008), and Daxx 
localization at these nuclear bodies are disrupted by viral proteins of both HSV-1 and HCMV 
(Everett et al., 1998; Saffert and Kalejta, 2006). Thus, it is important to investigate the sub-cellular 
location of BNRF1-Daxx interaction, and check if BNRF1 disrupts Daxx localization to the nuclear 
bodies. For immunofluorescence (IF) microscopy studies, we selected Hep2 carcinoma cell lines 
because of their larger size and prominent PML nuclear bodies, and their common use in many 
previous studies with herpesvirus protein interactions with PML-NBs. Hep2 cells were transiently 
transfected with empty FLAG vector (V) or BNRF1 constructs WT, d26, or DID. Cells were then 
fixed two days post transfection and subject to IF staining. We found that WT BNRF1 partially co-
localized with nuclear foci containing Daxx (Figure 2.4A, 2.10A and Table 2.1), PML (Figure 2.4B, 
2.10B and Table 2.1), and Sp100 (Figure 2.10D), suggesting that BNRF1 interacts with Daxx at 
the PML nuclear bodies. We also noticed that DID itself is sufficient for localizing to PML nuclear 
bodies, while the d26 deletion mutant showed a weak dispersed pattern in the cell (Figure 2.4A 
and B, 2.10 and Table 2.1). The co-localizations were also confirmed by line scan analysis, where 
the BNRF1 WT and DID intensity peaks overlap with Daxx and PML peaks (Figure 2.11). To 
ensure that the diffuse pattern of the d26 mutant is not due to deficient protein expression, the 
same set of transfected cells as used for IF were also assayed by Western blot for total 
expression levels of BNRF1 proteins (Figure 2.4D). We found that d26 protein was expressed at 
levels similar to that of WT, despite its diffuse staining in IF studies, confirming its protein 
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expression in the cells used in our microscopy study. These findings indicate that the interaction 
with Daxx is necessary and sufficient for BNRF1 to localize to the nuclear bodies. 
To understand the BNRF1 disruption of Daxx-ATRX complex in a sub-cellular spatial context, 
we also examined ATRX by IF in BNRF1-transfected Hep2 cells (Figure 2.4C and 2.10C). Again, 
we found ATRX foci co-localizing with WT BNRF1 and DID but not d26, which is also confirmed 
by line scan analysis (Figure 2.11C). However, we also found a substantial reduction in ATRX 
foci intensity when cells were transfected with WT BNRF1, but no apparent reduction when 
transfected with d26 or DID-mutants (Figure 2.4C). The failure of DID to disperse ATRX is 
consistent with its only partial disruption of ATRX from Daxx IP (Figure 2.3C). Quantification of 
Daxx (Figure 2.4E), PML (Figure 2.4F), and ATRX (Figure 2.4G) nuclear foci in BNRF1-
expressing cells compared to non-expressing cells revealed that BNRF1-expressing cells contain 
a significantly lower (p<0.0001) average number of ATRX nuclear foci than non-expressing cells 
(Figure 2.4G). In contrast, we found no significant difference in the number of Daxx (Figure 2.4E) 
and PML nuclear foci (Figure 2.4F) in BNRF1 transfected cells. Taken together, these results 
suggest that BNRF1 not only disrupts the Daxx-ATRX complex, but also actively disperses ATRX 
away from nuclear bodies. 
HSV-1 ICP0 and HCMV pp71 each induce the degradation of PML and Daxx proteins 
respectively, yet we did not observe any evidence of this with BNRF1 in our microscopy studies. 
To investigate the potential degradation of PML, Daxx and ATRX proteins by BNRF1, we 
examined the stability of these proteins in BNRF1 stably transfected cells (Figure 2.5A). 293T 
cells stably transfected with control vector (clone C) or WT BNRF1 (stable transfection clones 3 
and 9) were lysed and subject to Western blot analysis. We found no evidence of degradation or 
gross post-translational modification of PML, Daxx, nor ATRX in BNRF1-expressing cell lines. We 
also analyzed the protein stability of PML and Daxx in Hep2 cells transiently transfected with 
control vector, WT BNRF1 or d26, and again found no evidence of BNRF1-induced protein 
degradation (Figure 2.12). This suggests that BNRF1 does not mimic the protein degradation 
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function of HCMV pp71 or HSV-1 ICP0, but rather, disrupts Daxx-ATRX interactions through 
alternative mechanisms. 
The diffuse distribution of the BNRF1-d26 mutant raised the question of whether the Daxx 
interaction domain of BNRF1 correlated with nuclear localization. To test this, we utilized 
biochemical fractionation methods to isolate nuclear and cytoplasmic proteins from 293T cells 
(Figure 2.5B). We found that WT BNRF1 localized to both cytoplasmic (~60%) and nuclear (40%) 
fractions. The d26 mutant, which is deficient in both Daxx interaction and nuclear bodies 
localization, was expressed at lower amounts yet showed a cytoplasmic to nuclear distribution 
similar to WT (Figure 2.5B). This is consistent with d26 having a weak diffuse nuclear and 
cytoplasmic staining in IF (Figure 2.4). Meanwhile, the DID mutant, which binds Daxx and co-
localizes with PML nuclear bodies in the nucleus, was isolated at low, yet detectable levels in the 
nucleus; although substantially more was recovered in the cytoplasmic fraction. The efficiency of 
the fractionation was confirmed by the presence of PARP1 exclusively in the nuclear fractions, 
and α-tubulin exclusively in the cytoplasm. These findings suggest that BNRF1 can localize to 
both cytoplasmic and nuclear compartments, and that the Daxx interaction domain might 
contribute partially to the nuclear entry or stability of BNRF1. 
 
2.8 The Daxx interaction domain is required for BNRF1 to support EBV primary 
infection 
A previous study using an EBV bacmid with a BNRF1-knockout demonstrated that BNRF1-
mutant virions can be generated from producer 293 cells and can enter the cytosol of infected B-
cells; yet mutant virus failed to express one of the first expressed latent genes, EBNA2, upon 
primary infection of B cells, and were incapable of inducing B-cell proliferation (Feederle et al., 
2006). To understand the role of BNRF1-Daxx interaction in primary infection, we took a 
complementation rescue approach with the BNRF1-mutant virus. 293 cells stably transfected with 
either wild type or BNRF1-knockout EBV bacmids were used for virus production (Figure 2.6). As 
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the EBV bacmids also encode GFP, cells infected with this bacmid-derived virus could be 
visualized by the presence of green fluorescence. To induce viral production, bacmid containing 
cells were co-transfected with the EBV transactivator Zta and BALF4. To complement for BNRF1 
deletion, production cells were also transfected with either control vector, WT BNRF1 (WT), or the 
BNRF1 deletion mutant (d26) which fails to interact with Daxx. Three days after transfection, the 
media was collected and used to infect primary B cells isolated from human peripheral blood 
mononuclear cells (PBMCs). We detected high-levels of GFP positive proliferating B-cell clusters 
when infected with virus generated from wild type bacmid (Figure 2.6Ai), but no GFP positive or 
clumped cells were detected when infected with no virus (Figure 2.6Aii) or virus from un-
complemented ΔBNRF1 bacmids (Figure 2.6Aiii). However, when ΔBNRF1 virus was 
complimented with WT BNRF1 we were able to detect GFP positive cells and proliferating B-cell 
clusters (Figure 2.6Aiv). Notably, ΔBNRF1 virus complimented with the d26 mutant BNRF1 failed 
to express GFP or induce B cell proliferation (Figure 2.6Av), showing a similar defect as ΔBNRF1 
virus with no complementation. Quantification of at least three independent infections confirmed 
that GFP positive and proliferating B-cells were detectable only when ΔBNRF1 bacmid virus was 
complemented with WT, but not with d26 mutant BNRF1 (Figure 2.6B). To ensure the infections 
between each complemented virus were comparable, virus titer was quantified by real time PCR 
for virion DNA. The viral titers of either empty vector or WT BNRF1 complemented virus was 
found to be similar, while some reduction in virus titer was observed with d26 virus (Figure 2.6C). 
We also tested by Western blotting for incorporation of FLAG-BNRF1 proteins in virions, and 
found that WT and d26 mutant BNRF1 proteins were both packaged into virions to similar per 
particle levels (Figure 2.6D). These findings confirm that BNRF1 is required for primary infection 
of B-cells, and suggests that the Daxx interaction domain of BNRF1 is important for this function. 
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2.9 BNRF1 promotes expression of the immediate early gene BZLF1 
Other herpesvirus tegument proteins that interact with Daxx and ATRX have been shown to 
function in the transcription activation of viral genes during primary infection (Woodhall et al., 
2006). To investigate the role of BNRF1 on viral gene transcription early after primary infection, 
we infected human B-lymphocytes purified from PBMCs with the ΔBNRF1 virus complemented 
with empty FLAG-vector, WT BNRF1 or d26 mutant BNRF1 (Figure 2.7A). Viral gene expression 
in these newly infected cells was assayed at four days post infection using Reverse Transcription 
qPCR (RT-qPCR). We found that WT BNRF1 complementation induced an up-regulation of 
EBNA1, EBNA2 and BZLF1 mRNA expression compared with non-complemented virus or the 
d26-mutant complementation. Interestingly, background levels of BZLF1 expression were 
detectable in non-complemented and d26 mutant infections, suggesting that BNRF1 may only 
partly enhance BZLF1 expression, which can occur at low levels independently of BNRF1. 
To investigate the potential mechanism of BNRF1 in viral gene regulation, we first tested the 
effect of BNRF1 on reporter plasmids using transient transfection assays, but found no consistent 
effect on candidate viral promoters (data not shown). We reasoned that reporter plasmids may 
lack essential BNRF1 target elements or chromatin assembly, and therefore assayed BNRF1 
activity on EBV bacmid genomes after transfection into 293 cells (Figure 2.7B). EBV bacmid DNA 
(Bac36) and either empty FLAG-vector, WT BNRF1, or the d26 mutant BNRF1 were co-
transfected into 293 cells and assayed 3 days post transfection for viral gene expression using 
RT-qPCR. We found that WT BNRF1 promoted a robust expression of BZLF1 transcripts (~20 
fold), which was not observed in vector control or the d26 mutant (Figure 2.7B). BNRF1 also 
increased EBNA2 mRNA (~3 fold) relative to vector control, but this was not significantly 
increased relative to that of the d26 mutant. These studies suggest that BNRF1 can activate the 
expression of the EBV immediate early gene BZLF1 in the context of the viral genome, and in the 
absence of other virion-delivered tegument proteins. 
 
31	  
	  
2.10 BNRF1 does not substitute for ICP0 in HSV-1 intection 
As BNRF1 disrupts the cellular PML nuclear bodies, we next tested if BNRF1 may substitute 
for the best-studied PML-disrupting viral protein, ICP0 of HSV-1. To test this hypothesis, 293T 
cells stably expressing FLAG-vector or FLAG-BNRF1 were test infected with HSV-1 (KOS strain, 
Figure 2.8A) or an ICP0-null mutant (strain 7134, Figure 2.8B). HSV-1 infection efficiency in these 
cells was assayed via qPCR quantification of viral DNA at multiple time points post infection. 
Comparing the infections in BNRF1-positive with BNRF1-negative control cells, we found that 
BNRF1 promoted HSV-1 infection, with viral DNA copy numbers at 23 hours post infection (hpi) 
about 5-fold higher in the presence of BNRF1 (Figure 2.8). This supports BNRF1 as a viral 
counter defense against antiviral resistances. However, this BNRF1-induced 5-fold higher DNA 
copy number is seen regardless of the presence or absence of ICP0. Most importantly, BNRF1 
does not rescue ICP0-null virus infection rates up to that of wildtype virus. This suggests that 
BNRF1 is either much weaker then ICP0, or it may target differing cellular pathways. 
 
2.11 Daxx and ATRX restrict viral reactivation from latency 
The previous experiments suggest that BNRF1 can function during tegument delivery in 
early infection, as well as after de novo synthesis, perhaps regulating the transition from latent to 
lytic infection. To explore the role of Daxx and ATRX in the context of EBV latent to lytic gene 
regulation, we test the effects of Daxx and ATRX knockdown on viral lytic gene expression in 
Mutu I cells, an EBV-latently infected Burkitt's lymphoma cell line (Figure 2.9). Mutu I cells were 
transduced with puromycin resistant lentivirus carrying either non-targeting shRNA (shNeg), 
shRNA against Daxx (shDaxx), ATRX (shATRX), or ZEB1 (shZEB1.1) which acts as a positive 
control for reactivation. ZEB1 has been shown to repress Zta expression, and shRNA depletion of 
ZEB1 can reactivate lytic gene expression in several cell types (Ellis et al., 2010; Kraus et al., 
2003; Yu et al., 2007). Mutu I cells were harvested 9 days after shRNA transduction and selection, 
and then tested for viral reactivation by Western blot and FACS (Fig 9). Western blot analysis of 
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whole cell lysates (Figure 2.9A and B) revealed that knockdown of either Daxx or ATRX induced 
a reactivation of EBV early antigens, as shown by increased band intensities of both the 
immediate early gene Zta (2-fold) and the lytic early antigen EA-D (3-fold). These induction levels 
are comparable to that observed with the shZEB1.1 positive control. The efficiency of shRNA-
mediated knockdown was confirmed by the loss of Daxx, ATRX and ZEB1 bands in the 
corresponding lanes (Figure 2.9A). We also verified reactivation by flow cytometry quantification 
of the EBV viral capsid antigen VCA on cells from three independent shRNA-treatments (Figure 
2.9C), where we observed an approximately 6-to-10-fold induction by either Daxx or ATRX 
depletion. These findings indicate that the depletion of either Daxx or ATRX can promote viral 
lytic gene expression from latently infected B-cells, and suggest that BNRF1 disruption of the 
Daxx-ATRX complex contributes to viral gene control during early infection and reactivation. 
2.12 Discussion 
The specific class of antiviral defense dubbed the intrinsic immunity (Bieniasz, 2004; 2007) 
plays a broad and general role in restricting viral infection. PML-NBs and its associated proteins 
such as PML, Sp100, Daxx and ATRX, have been extensively studied as cellular defenses 
against herpesviruses, specifically with the alphaherpesvirus HSV-1 and betaherpesvirus HCMV. 
Upon the early stages of infection right after cell entry, HSV-1 and HCMV utilize viral proteins that 
effectively disrupt the structure and disable the function of the PML-NBs in restricting viral gene 
expression and replication. However, the gammaherpesvirus EBV has been relatively less 
studied in terms of how it counteracts these cellular resistances upon primary infection or 
reactivation. We show here that the major tegument protein of EBV, BNRF1, interacts with Daxx 
(Figures 2.1–2.3, 2.10–2.11) and disrupts its ability to form a complex with ATRX or recruit ATRX 
to PML-NBs (Figures 2.3–2.4, 2.10–2.11). Moreover, we show that BNRF1 functionally promotes 
viral early gene expression with a preference for the activation of the immediate early gene 
BZLF1, and to a lesser extent the latent activator EBNA2 (Figures 2.6–2.7). These findings 
indicate that EBV, like its relatives HSV1 and HCMV, encodes a viral tegument protein that 
targets PML-NB components to counteract antiviral defenses and promote viral gene expression. 
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Daxx is a prominent PML-NB component, but is also associated with a diverse, yet non-
mutually exclusive variety of cellular functions, including the regulation of apoptosis, chromatin 
remodeling, gene repression, and antiviral resistance (Lindsay et al., 2008; Michaelson, 2000). 
Daxx is a primary target of the HCMV pp71 protein, which both binds and induces the 
degradation of Daxx (Lukashchuk et al., 2008). Like HCMV pp71, BNRF1 binds Daxx and 
prevents the Daxx-interaction partner, ATRX, from associating with Daxx and localizing to PML-
NBs. BNRF1 and pp71 are both tegument proteins, whose pre-made nature likely provides them 
with a temporal advantage to disarm cellular repression machinery without the prior need of viral 
gene transcription. However, unlike HCMV pp71, BNRF1 does not induce Daxx degradation, 
which remains prominently associated with PML-NBs when BNRF1 is expressed (Figs 2.2–2.5). 
BNRF1 and pp71 share no obvious amino acid sequence similarity, and the Daxx interaction 
domains of these two proteins vary significantly in amino acid composition and size of the 
interaction domains. These findings suggest that BNRF1 is a functional homologue of pp71, but 
utilizes a distinct mechanism for the dissociation of ATRX from PML-NBs. 
Herpesvirus tegument proteins have been implicated in the determination of viral lytic or 
latent gene expression programs. Restriction of tegument protein entry into the nucleus, as has 
been shown for HCMV pp71 and HSV VP16, correlates with the establishment of latency (Saffert 
and Kalejta, 2006), suggesting that tegument proteins may play a critical role in determining lytic 
or latent gene expression programs. Interestingly, we found that the Daxx-interaction deficient 
BNRF1 mutant d26, which fails to interact with Daxx, showed a weak diffuse subcellular 
distribution instead of the punctate nuclear dots of WT BNRF1 (Figure 2.4 and 2.10). Similarly, 
biochemical fractionation studies (Figure 2.5B) suggest that while BNRF1 can localize to both the 
cytoplasm and nucleus, it may require the Daxx-interaction domain to efficiently accumulate in the 
nucleus. Potentially related is the observation that HCMV pp71 translocation to PML-NBs is also 
dependent on its interaction with Daxx (Hofmann et al., 2002). Selective cytoplasmic retention of 
several herpesvirus tegument proteins, including pp71 and VP16, may play a critical role in 
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determining lytic or latent gene expression programs (Kolb and Kristie, 2008). We suspect that 
BNRF1 might be subject to similar regulation through its PML-NB localization. 
Daxx and ATRX are known to play a global role in the control of cellular and viral gene 
expression and chromosomal structure. Daxx itself has been shown to associate with HDACs and 
to function as a global repressor of transcription (Hollenbach et al., 2002; Li et al., 2000a). The 
Daxx-ATRX complex has in vitro chromatin remodeling activities (Xue et al., 2003) and can 
function as a histone H3.3 chaperone (Lewis et al., 2010). Recent studies suggest also that 
ATRX interacts with G-rich repeat chromatin regions (Law et al., 2010), and in collaboration with 
Daxx load histone variant H3.3 onto pericentromeric and telomeric chromatin (Drane et al., 2010; 
Goldberg et al., 2010; Lewis et al., 2010). H3.3 is generally associated with open chromatin and 
active transcription when loaded by the histone chaperone HIRA (Loyola and Almouzni, 2007). 
However, the Daxx-ATRX complex loaded H3.3 has been found to facilitate transcription from 
pericentromeric regions (Drane et al., 2010) but repress transcription from telomeric regions 
(Goldberg et al., 2010). Interestingly, HIRA-loaded H3.3 can facilitate the lytic replication of HSV-
1 during the early steps of infection (Placek et al., 2009). Furthermore, the Daxx-degrading pp71 
blocks the establishment of heterochromatin on the HCMV Major Immediate Early Promoter 
(MIEP) region (Woodhall et al., 2006). These findings underscore the importance of host 
chromatin regulatory mechanisms in the control of herpesvirus infection. We suspect that the viral 
gene activation function of BNRF1 (Figure 2.7) is likely to be mediated by chromatin-dependent 
processes since we failed to observe consistent transcription activation when assayed in transient 
plasmid-based reporter assays using EBV promoters for BZLF1 (Zp) or EBNA2 (Cp or Wp) (data 
not shown). We propose that BNRF1 stimulates EBV early gene activity through de-repression of 
the Daxx-ATRX mediated chromatin repression mechanism, perhaps similar to that of pp71 de-
repression of the HCMV MIEP locus. However, the precise molecular mechanism through which 
BNRF1 activates early gene transcription through the disruption of ATRX-Daxx interaction 
remains to be investigated. 
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While not explored yet, it is also not known if the FGARAT enzyme-homology domain of 
BNRF1 has any function in the context of supporting viral infection. This enzyme homology is 
conserved among all gammaherpesvirus orthologues of BNRF1, including the KSHV and MHV68 
ORF75 family members. Despite significant sequence similarity with BNRF1, KSHV and MHV68 
ORF75 proteins do not appear to interact with Daxx (data not shown). However, MHV68 ORF75c 
targets PML-NBs through the degradation of PML (Gaspar et al., 2008; Ling et al., 2008), an 
activity that we did not observe with BNRF1. Thus, while these tegument family members share 
the FGARAT homology regions, and may similarly target components of the PML-NBs, they 
appear to target different proteins and utilize distinct mechanisms. It is also important to note that 
the disruption of ATRX by BNRF1 was partially dependent on the FGARAT domain, since the 
DID alone, which binds Daxx efficiently, only partially disrupt ATRX binding in IP assays (Figs 2.2 
and 2.3) while not causing any significant ATRX dispersion from PML-NBs in IF assays (Figure 
2.4). Also, deletions within the FGARAT domain (d3 and d4) resulted in a mutant BNRF1 that co-
precipitated with ATRX, creating a gain of function not seen with WT BNRF1. All of this suggests 
that the FGARAT domain may play a regulatory role in BNRF1 interactions with Daxx and ATRX. 
In conclusion, our data demonstrates a novel example of herpesvirus tegument protein 
interacting with components of the cellular antiviral resistance. BNRF1 interaction with Daxx may 
provide several functions, including the establishment of a chromatin structure conducive to viral 
early gene activity. Our findings demonstrate that EBV, like other herpesviruses, confront the 
PML-NB associated intrinsic defenses through a viral factor that is available and active upon the 
early stages of infection, and shed light into the critical control mechanisms that govern the early 
events of EBV infection before the establishment of latency. 
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2.14 Figures 
 
Figure 2.1. BNRF1 binds the cellular protein Daxx 
(A) Colloidal blue stained SDS-PAGE of FLAG-immunoprecipitated BNRF1 and interacting 
partners. 293T cells were stably transfected with empty FLAG vector (V) or FLAG-tagged BNRF1 
(B). Cell lysates were subject to Immunoprecipitation (IP) by anti-FLAG antibodies, then analyzed 
by SDS-PAGE. Bands unique to lane B were cut out and identified by LC/MS/MS. (B) IP 
confirmation of BNRF1/Daxx interaction. 293T cells were transiently transfected with empty 
vector (V) or wild-type BNRF1 (B). Cells harvested two days post-transfection were subject to IP 
with non-specific IgG, anti-FLAG or anti-Daxx antibodies, and analyzed by Western blot (WB) 
with anti-FLAG or anti-Daxx antibodies. (C) Summary of LC/MS/MS data from FLAG-BNRF1 
purification. Genebank accession number (GI), percent of peptide coverage, number of peptides 
identified, and protein name are indicated. 
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Figure 2.2. Mapping the Daxx-interaction domain on BNRF1, and the effect of 
BNRF1 on the Daxx-ATRX complex. 
(A) Diagram of wild-type BNRF1 (WT) and mutation constructs with 300 aa deletions (d1-
d5). Dark gray block denotes the amino-terminal FLAG tag. Light gray blocks denote regions with 
sequence homology to the cellular enzymes Aminoimidazole ribonucleotide synthetase (AIR_S) 
and Type 1 glutamine amidotransferase (GATase1, an enzymatic domain of FGARAT), as 
identified by the National Center for Biotechnology Information (NCBI) conserved domain search. 
(B) IP pull down analysis of the BNRF1 deletion constructs. 293T cells were either transfected 
with empty FLAG vector (V), the BNRF1 constructs WT, or mutants d1-d5. Cell lysates of 
transfected cells were then subject to IP pull-downs with non-specific IgG, anti-FLAG, or anti-
Daxx- antibodies, then Western blots were probed for Daxx (top panels), and FLAG-tagged 
proteins (lower panels). Input is shown for each mutant in the left most panels. 
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Figure 2.3. The Daxx-interaction domain on BNRF1 is located between sites 360-
600 aa, and BNRF1 disrupts Daxx-ATRX binding. 
(A) Diagram of BNRF1 mutation constructs with 60 aa deletions (d21–d25) within the 360–
600 aa Daxx-interaction domain (DID) and the DID only. Blocks in the diagram drown as Figure 
2.2A. (B) IP analysis of BNRF1 60 aa deletion constructs. 293T cells were transfected with 
various BNRF1 expression vector constructs, and cell lysates were subject to IP pull downs with 
non-specific IgG and anti-FLAG antibodies, then Western blots were probed for Daxx (top panel), 
or FLAG-tagged proteins (lower panel). (C) IP analysis of 293T cells transfected with vector 
control (V), WT BNRF1 (WT), BNRF1 deletion mutants d22, d26, or DID. Input, IgG control IP, 
FLAG IP, or Daxx IP (panels left to right) as indicated above each panel. Western blots of IPs 
were probed with antibody to Daxx, ATRX, PML, FLAG, or Actin, as indicated to the left of each 
panel. (D) IP Western of 293T cells transfected with vector control (V), WT-BNRF1 (WT), or 
BNRF1 deletion mutants d1, d2, d3, d4, or d5. FLAG-IPs were analyzed by Western blot with 
antibodies to ATRX (top panel) Daxx (middle panel), or FLAG (lower panel). 
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Figure 2.4. BNRF1 co-localizes with Daxx at PML-NBs and disperses ATRX from 
PML-NBs. 
Hep2 cells were transfected with either FLAG empty vector, WT BNRF1, or the deletion 
constructs d26 and DID. Cells were fixed 2 days post transfection and co-stained with anti-FLAG, 
and DAPI, and either anti-Daxx (A), anti-PML (B), or anti-ATRX (C) antibodies. Yellow regions in 
the merged panels denote co-localization of red and green signals. Remaining un-fixed, 
transfected Hep2 cells were subject to cell lysate Western blot analysis to confirm transfection 
efficiency and expression levels of the BNRF1 constructs (D). The number of nuclear bodies per 
cell nucleus was quantified by computational analysis of immunofluorescent microscopy images. 
A total of ten 40x magnification microscopy images of random fields were analyzed for each foci 
count. Foci counts of either Daxx (E), PML (F), or ATRX (G) were grouped into BNRF1 non-
expressing and expressing sets. Bars on scatter plots denote the average foci per cell. 
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Figure 2.5. Stability and subcellular fractionation of BNRF1 proteins. 
(A) FLAG vector (clone C) or FLAG-BNRF1 (clones 3 and 9) stably transfected 293T cells 
were lysed and analyzed by Western blot. Blots were probed with antibodies to PML, Daxx, 
ATRX, FLAG (BNRF1), or Actin, as indicated to the right. (B) 293T cells transfected with FLAG 
vector (V), WT-BNRF1 (WT), d26, or DID mutant for 48 hrs were prepared as total cell extracts 
(input), cytoplasmic or nuclear fractions. Transfected cells fractions were assayed by Western 
blot with antibody to FLAG (BNRF1), PARP1 (nuclear marker) or αTubulin (cytoplasmic marker). 
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Figure 2.6. △BNRF1 mutant virus infection can be rescued by ectopic 
complementation with wild type, but not Daxx-interaction-deficient BNRF1. 
Primary B cells were infected with equal volumes of GFP expressing virus, either produced 
from wild type bacmids or △BNRF1 mutant virus complemented with empty FLAG vector, wild 
type, or the d26 Daxx-interaction-deficient mutant BNRF1. Infected cells would express the GFP 
carried in the virus. Infection rate as shown in fluorescent microscopy photos (A), or a manual 
count of the average number of GFP-positive cells per well (B). Aliquots of the virus used for 
infection were isolated for measurement of viral titers by real-time PCR analysis of the number of 
viral OriLyt DNA copy numbers (C). Viral particles reconstituted with FLAG vector, FLAG-tagged 
WT-BNRF1 or d26 mutant were concentrated and analyzed by Western blot with antibody to 
FLAG (D). 
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Figure 2.7. BNRF1 promotes viral gene expression. 
(A) Primary B cells were infected with virus produced from △BNRF1 mutant bacmids either 
complemented with empty vector, wild type BNRF1 or the d26 Daxx-interaction-deficient mutant 
BNRF1. Virus infected cells were subject to reverse transcription PCR assay of viral gene 
expression for EBNA1, EBNA2, or BZLF1. (B) 293HEK cells were co-transfected with wild type 
EBV genomes and either empty vector, WT BNRF1 or the d26 Daxx-interaction-deficient mutant 
BNRF1. Transfected cells were subject to reverse transcription PCR assay of viral gene 
expression for EBNA1, EBNA2, EBNA3C, or BZLF1. 
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Figure 2.8. BNRF1 promotes HSV-1 infection but doesn’t substitute for ICP0 
293T cells stably transfected with either FLAG-vector or FLAG-BNRF1 were test infected 
with either the wildtype (KOS strain) (A) or ICP0-null (7134 strain) (B) HSV-1. Infected cells were 
harvested at various time points in a time course, cellular DNA extracted and subject to qPCR 
quantification of intracellular HSV-1 DNA copy number.  Relative viral DNA copy number 
calculated as HSV Thymidine Kinase promoter readouts normalized to cellular p21; error bars, 
SD.  
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Figure 2.9. ATRX and Daxx depletion leads to reactivation of latent EBV. 
Mutu I cells were transduced with lentivirus shRNA with non-targeting sequence (shNeg), or 
targeting for ATRX (shATRX), Daxx (shDaxx) or positive control ZEB1 (shZEB1.1). Transduced 
cells were selected for puromycin resistance for 9 days and then assayed by Western blot with 
antibodies to Zta, EA-D, Daxx, ATRX, ZEB1, or αTubulin, as indicated and visualized by HRP (A) 
and densitometric scanning of Western blot band intensities (B). Three replicates of Mutu I 
transduced as described above were assayed by flow cytometry with antibody to EBV viral capsid 
antigen VCA and quantified as % VCA positive fold change relative to shNeg. Error bars denote 
the standard error among the independent experiments (C). 
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Figure 2.10. BNRF1 co-localizes with Daxx at PML-NBs and disperses ATRX from 
PML-NBs.  
Hep2 cells transfected with FLAG-BNRF1 constructs were fixed 2 days post transfection and 
co-stained with anti-FLAG, and DAPI, and either anti-Daxx (A), anti-PML (B), anti-ATRX (C), or 
anti-Sp100 (D) antibodies. Yellow regions in the merged panels denote co-localization of red and 
green signals. 
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Figure 2.11. Signal intensity profiles analysis of BNRF1 co-localization with PML 
nuclear bodies.  
Color channel merged panels from Figure 2.4 were subject to line scan signal intensity 
analysis as (Shanbhag et al., 2010), to test overlaps of BNRF1 signals with Daxx (A), PML (B), 
and ATRX (C). Intensities of red and green signals were plotted bellow each photo, where the x-
axis runs from left to right along the yellow line drawn across several nuclear foci in each photo. 
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Figure 2.12. Time-course study of the effects of BNRF1 on PML and Daxx protein 
stability.  
Hep2 cells were transfected with vector control, WT BNRF1, or BNRF1-d26 mutant 
expression vectors. Total cell lysates were analysed by Western blot at 0, 12, 24, or 48 hrs post-
transfection. Western blots were probed with antibodies to PML, Daxx, FLAG (BNRF1), or Actin, 
as indicated to the right. 
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2.15 Tables 
Table 2.1 Percentage of BNRF1 foci overlap with Daxx or PML foci, as observed by 
IF microscopy 
BNRF1 WT with Daxx n=21  BNRF1-DID with Daxx n=23 
89.92% BNRF1 foci colocalize with Daxx  84.65% DID foci colocalize with Daxx 
93.98% Daxx foci colocalize with BNRF1  97.16% Daxx foci colocalize with DID 
       
BNRF WT with PML n=19  BNRF1-DID with PML n=22 
78.48% BNRF1 foci colocalize with PML  72.84% DID foci colocalize with PML 
58.77% PML foci colocalize with BNRF1  23.41% PML foci colocalize with DID 
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3. Viral Reprogramming of the Daxx-Histone H3.3 Chaperone During EBV Early 
Infection 
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3.1 Abstract 
Host	  chromatin	  assembly	  can	  function	  as	  a	  barrier	  to	  viral	  infection.	  	  Epstein-­‐Barr	  virus	  (EBV)	  
establishes	  latent	  infections	  in	  which	  all	  but	  a	  few	  viral	  genes	  are	  repressed	  by	  chromatin.	  	  We	  
demonstrate	  that	  during	  early	  infection,	  the	  EBV	  tegument	  protein	  BNRF1	  reprograms	  the	  
histone	  H3.3	  chaperone	  Daxx	  to	  assemble	  permissive	  chromatin	  on	  viral	  regulatory	  elements	  
essential	  for	  latent	  infection.	  	  We	  demonstrate	  that	  BNRF1	  substitutes	  for	  the	  repressive	  co-­‐
chaperone	  ATRX	  to	  form	  a	  ternary	  complex	  of	  BNRF1-­‐Daxx-­‐H3.3-­‐H4,	  using	  co-­‐
immunoprecipitation	  and	  size	  exclusion	  chromatography	  with	  highly	  purified	  components.	  	  
Fluorescence	  recovery	  after	  photobleaching	  (FRAP)	  assays	  were	  used	  to	  demonstrate	  that	  
BNRF1	  promotes	  global	  mobilization	  of	  cellular	  histone	  H3.3.	  	  Mutation	  of	  putative	  nucleotide	  
binding	  motifs	  on	  BNRF1	  attenuates	  the	  displacement	  of	  ATRX	  from	  Daxx.	  	  We	  also	  show	  by	  
immunofluorescence	  (IF)	  combined	  with	  fluorescence	  in	  situ	  hybridization	  (FISH)	  that	  BNRF1	  is	  
important	  for	  the	  dissociation	  of	  ATRX	  and	  Daxx	  from	  nuclear	  bodies	  during	  de	  novo	  infection	  of	  
primary	  B-­‐lymphocytes.	  	  Virion-­‐delivered	  BNRF1	  suppresses	  Daxx-­‐ATRX-­‐mediated	  H3.3	  loading	  
on	  viral	  chromatin	  as	  measured	  by	  chromatin	  immunoprecipitation	  (ChIP)	  assays	  and	  enhances	  
viral	  gene	  expression	  during	  early	  infection.	  We	  propose	  that	  EBV	  tegument	  protein	  BNRF1	  
replaces	  ATRX	  to	  reprogram	  Daxx-­‐mediated	  H3.3	  loading,	  in	  turn	  generating	  chromatin	  suitable	  
for	  latent	  gene	  expression.	  
	  
3.2 Importance 
Epstein-Barr Virus (EBV) is a human herpesvirus that efficiently establishes latent infection 
in primary B-lymphocytes.  Cellular chromatin assembly plays an important role in regulating the 
establishment of EBV latency.  We show that the EBV tegument protein BNRF1 functions to 
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regulate chromatin assembly on the viral genome during early infection.  BNRF1 alters the host 
cellular chromatin assembly to prevent anti-viral repressive chromatin, and establish chromatin 
structure permissive for viral gene expression and the establishment of latent infection. 
 
3.3 Introduction 
Cellular chromatin assembly is a highly regulated process required for the control of 
programmed gene expression and genome stability (Burgess and Zhang, 2013).  DNA viruses 
that enter the nucleus are subject to chromatin assembly and the formation of higher order 
chromatin structures that facilitate viral gene expression and replication.  Yet, cellular-mediated 
chromatin assembly may also function to resist viral infection (Knipe and Cliffe, 2008; Knipe et al., 
2013).  To ensure the expression of viral genes essential for productive infections, viruses 
encode numerous factors that counteract cellular anti-viral resistances such at chromatin-
mediated silencing (Boutell and Everett, 2013; Saffert and Kalejta, 2008). The mechanisms of 
viral modulation of chromatin assembly are not completely understood and may be nuanced for 
different virus families. 
Almost all viruses that enter the nuclear compartment interact with prominent nuclear 
structures referred to as the PML nuclear bodies (PML-NB, also called ND10) (Bernardi and 
Pandolfi, 2007; Everett and Chelbi-Alix, 2007; Saffert and Kalejta, 2008).  PML-NBs are 
interferon-inducible structures that frequently form adjacent to viral genomes that just entered the 
nucleus.  The Promyelocytic Leukemia (PML) protein forms a major structural component of the 
PML-NBs that typically also include Sp100, Daxx, and ATRX (Bernardi and Pandolfi, 2007). They 
are disrupted by a variety of virus-encoded proteins, strongly suggesting that PML-NBs are 
involved in antiviral resistance (Maul et al., 2000).  Most virus-targeted PML-NB components such 
as Daxx, ATRX, and Sp100, are involved in chromatin regulation and gene repression. Sp100 
represses gene expression from foreign DNA (Newhart et al., 2013a; Wilcox et al., 2005). Daxx is 
a transcription co-repressor that interacts with cellular transcription factors (Emelyanov et al., 
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2002; Lehembre et al., 2001; Li et al., 2000b; Michaelson and Leder, 2003; Michaelson et al., 
1999) and heterochromatin associated factors such as histone deacetylases (HDACs) and DNA 
methyltransferase I (DNMT I) (Hollenbach et al., 2002; Li et al., 2000a; Michaelson et al., 1999; 
Muromoto et al., 2004). ATRX, a protein with a SWI/SNF-like ATPase motif (Picketts et al., 1996), 
is associated with the establishment of heterochromatin (Baumann et al., 2010; Kernohan et al., 
2010).  More recently, Daxx has been found to form with ATRX a chromatin remodeling complex 
that acts as a histone chaperone of the histone variant H3.3 (Lewis et al., 2010; Xue et al., 2003). 
Histone H3.3 is loaded on chromatin in a DNA replication-independent manner, while H3.1 is 
typically assembled by CAF-I during DNA replication (Loyola and Almouzni, 2007).   H3.3 can be 
loaded onto transcriptionally active regions by the histone chaperone HIRA (Ahmad and Henikoff, 
2002).  In contrast, Daxx and ATRX have been found to load histone H3.3 onto pericentric and 
sub-telomeric chromatin (Goldberg et al., 2010) and are associated with the silencing of 
transcription from these regions. Furthermore, Sp100, Daxx, and ATRX have been reported to 
orchestrate host-induced repression of viral gene expression shortly after viral entry. PML and 
Sp100 represses herpes simplex virus (HSV-1) gene expression (Negorev et al., 2006); whereas 
Daxx and ATRX have been reported to setup heterochromatic markers on viral genomes of both 
human cytomegalovirus (HCMV) and adenovirus (Ad5) (Schreiner et al., 2013; Woodhall et al., 
2006). 
Epstein-Barr virus (EBV) is a human gammaherpesvirus that is associated with several 
malignancies, including Burkitt's lymphoma and nasopharyngeal carcinoma (Thorley-Lawson and 
Allday, 2008). EBV is notable for its propensity to establish latent infections in human B 
lymphocytes where the viral genome persists as a chromatinized episome expressing only a few 
viral genes (Lieberman, 2013; Young and Rickinson, 2004).  It is thought that viral chromatin 
assembly during primary infection is an important regulator of early viral gene expression and the 
establishment of successful latent infection (Lieberman, 2006).  The establishment of EBV 
latency requires intricate chromatin control in order to limit viral gene expression to a small 
number of latency-associated genes.  However, little is known of how this latent infection is 
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established upon the early stages of primary infection, which has been referred to as the pre-
latent phase (Kalla and Hammerschmidt, 2012).  Importantly, viral chromatin assembly and 
epigenetic programming is thought to initiate during the pre-latent phase. 
The EBV-encoded tegument protein BNRF1 is among the most abundant viral proteins 
brought into host cells by the infecting virions (Johannsen et al., 2004).  It is a member of a highly 
conserved family found in all gammaherpesviruses, including KSHV ORF75 (Full et al., 2014), 
MHV68 ORF75c (Ling et al., 2008) and HVS ORF3 (Full et al., 2012).  Each family member 
contains sequence homology to the cellular purine biosynthesis enzyme 
phosphoribosylformylglycineamide amidotransferase (FGARAT). However, no enzymatic activity 
of these viral FGARAT-homology proteins have been reported.  All studied homologs have been 
reported to disrupt different components of PML-NB. EBV BNRF1 was previously reported to be 
important for EBV early infection (Feederle et al., 2006).  We recently found that BNRF1 
dissociates ATRX from Daxx, and promotes viral gene expression during primary infection (Tsai 
et al., 2011).  Here, we investigate the mechanism through which BNRF1 modifies the histone 
H3.3 chaperone function of Daxx.  We show that while displacing ATRX from Daxx, BNRF1 forms 
a stable complex with the histone chaperone complex consisting of Daxx and histone variant 
H3.3 and H4, displacing ATRX.  Consequently, BNRF1 increases histone H3.3 dynamics in the 
nucleus. During the pre-latency phase of EBV infection, the tegument-delivered BNRF1 promotes 
viral gene expression, increases the presence of transcriptionally active histone marker H3K4 tri-
methylation (H3K4me3), and prevents the deposition of histone H3.3, Daxx, and ATRX on latency 
control elements. We propose that BNRF1 replaces the chaperone-guiding function of ATRX to 
allow productive chromatin assembly on EBV genomes during primary infection of B-lymphocytes, 
in turn allowing the expression of viral latent genes and the establishment of latent infection. 
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3.4 BNRF1 interacts with the histone binding domain of Daxx 
Daxx and ATRX form a histone H3.3 chaperone complex (Lewis et al., 2010), the structure 
of which was recently published (Elsässer et al., 2012). We first sought to locate the site on Daxx 
that BNRF1 interacts with, specifically asking if this interaction site overlaps with the Daxx histone 
binding domain (HBD). Several mutations were introduced into an HA-tagged Daxx expression 
construct, including deletions of sequences amino-terminal (∆N), within (∆HBD), and carboxy-
terminal (∆C) to the HBD at 178-389aa (Elsässer et al., 2012).  We also made an HBD-only 
construct by deleting N- and C-terminal flanking regions (Figure 3.1A). HA-Daxx constructs were 
co-transfected with FLAG-tagged BNRF1 into 293T cells, and cell lysates were subject to 
immunoprecipitation (IP) with FLAG-affinity beads. FLAG-BNRF1 co-purified with wild type (WT), 
∆N, ∆C and HBD-alone Daxx constructs but not ∆HBD (Figure 3.1B).  No Daxx proteins were 
immunoprecipitated in control transfections lacking FLAG-BNRF1 (Figure 3.1C). These results 
indicate that BNRF1 interacts selectively with the Daxx HBD domain. 
	  
3.5 BNRF1 forms a complex with Daxx and the histone H3.3/H4 tetramer 
The observation that BNRF1 interacts with the HBD of Daxx raised the possibility that 
BNRF1 may interfere with H3.3 loading by steric hindrance of Daxx-histone interaction. To test 
this possibility, we transfected 293T cells with HA-Daxx, with or without GFP-BNRF1, and FLAG-
tagged histone variant H3.1 or H3.3. Transfected cell lysates were subject to IP assay with anti-
Daxx or anti-FLAG (histone) (Figure 3.1D). As expected, anti-Daxx pulled down more FLAG-H3.3 
than FLAG-H3.1. Daxx also pulled down BNRF1 as previously reported (Tsai et al., 2011).  
However, the interaction was enhanced in the presence of FLAG-H3.3. Interestingly, FLAG-IP of 
histone H3.3 strongly pulled down both Daxx and BNRF1.  The BNRF1-Daxx-H3.3 interaction 
was selective for H3.3 since the FLAG pull down of H3.1 yielded three fold less Daxx and BNRF1 
than FLAG-H3.3 pull downs (Figure 3.1D, compare lanes 8 & 16, relative to lanes 2 & 10). The 
FLAG-H3.1 pulled down Daxx and BNRF1 bands were diminishingly weak, and there were no 
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previous reported interaction of Daxx with H3.1, thus this was treated as background. These 
results suggest that BNRF1, instead of disrupting Daxx-H3.3 binding, forms a complex with both 
Daxx and H3.3. 
To further test the formation of a BNRF1/Daxx/H3.3 complex, the Daxx interaction domain 
(DID) of BNRF1 (Tsai et al., 2011) was cloned as a GST-tagged construct (Figure 3.2A). Purified 
bacteria-produced GST-BNRF1-DID or GST alone was immobilized on glutathione sepharose 
beads and co-incubated with nuclear protein extract from Mutu I human B cell-lymphoma cell 
lines.  After extensive washing, interacting proteins were analyzed by Western blot. Both Daxx 
and histone H3.3 bound to GST-BNRF1-DID, but did not bind to the GST control (Figure 3.2B). 
Complex formation was specific to Daxx and H3.3 as neither ATRX nor the nuclear enzyme poly-
ADP ribose polymerase (PARP) were pulled down by GST-BNRF1-DID. These results further 
support the model that BNRF1 forms complexes with Daxx and histone H3.3. 
To determine whether formation requires any additional cellular factors, purified BNRF1-DID 
was incubated with purified bacteria-produced Daxx-HBD and recombinant histones H3.3 and H4. 
Complex formation was then analyzed by size exclusion chromatography (Figure 3.2C). As 
expected, H3.3/H4 ran with a stoichiometry of ~1:1, DAXX/H3.3/H4 as ~1:1:1, and BNRF1-DID 
as a monomer (~35 kD). When BNRF1-DID was co-incubated with pre-formed H3.3/H4 tetramers, 
the proteins migrated as distinctly separate peaks at positions identical to the individual 
components. However, when BNRF1-DID was incubated with pre-formed DAXX/H3.3/H4 
complexes, the proteins co-migrated, with an apparent stoichiometry close to 1:1 for BNRF1 with 
the DAXX/H3.3/H4 complex. This shift in mobility indicates that BNRF1 forms a co-complex with 
Daxx and H3.3/H4.  The findings also indicate that Daxx is required for BNRF1 interaction with 
histones H3.3 and H4. 
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3.6 The FGARAT homology domains of BNRF1 is important for Daxx-ATRX 
disruption 
The selective conservation of FGARAT-like amino acid sequences on the C terminal of all 
gammaherpesvirus BNRF1-ORF75 homologues suggest that this domain is functionally important 
for the gammaherpesvirus life cycle. While we have not yet found a functional link of BNRF1 with 
the conserved function of FGARAT in purine metabolism, we tested if this enzyme homology is 
linked to the ability of BNRF1 to disrupt the Daxx-ATRX complex. To test this hypothesis, we 
introduced small deletions targeting regions of BNRF1 that are homologous to conserved 
functional domains in the FGARAT gene (Figures 3.3A, 3.3B, aligned to the Salmonella 
Typhimurium homologue PurL). The dATPase (dA) and dPurL2 (dP) deletions target highly 
conserved domains with residues that were found to form hydrogen bonds with an ADP molecule 
co-crystalized with FGARAT (Anand et al., 2004) while the dGATase1 deletion (dG) covers 
residues important in the glutaminase domain of FGARAT. The ability of these mutants to interact 
with Daxx and disrupt Daxx-ATRX binding was tested by IP-Western blot assays performed on 
293T cells transfected with empty FLAG vector (V), FLAG tagged wild type (WT) or enzymatic 
mutants (dP, dA, dG) of BNRF1 (Figure 3.3C). We found that wild type and all enzymatic mutants 
of FLAG-BNRF1 co-immunoprecipitated with Daxx. Yet, in contrast to WT BNRF1, none of the 
mutants could disrupt ATRX interaction with Daxx (Figure 3.3C lane 17, ATRX panel). These 
results suggest that the FGARAT homology of BNRF1 is important for displacing ATRX from the 
Daxx-ATRX complex and thus critical for its biochemical function. 
 
3.7 BNRF1 co-purifies with ATPase activity 
We next tested if BNRF1 retains any enzymatic activity from the FGARAT homology. As 
FGARAT is an amidotransferase with ATPase activity, we tested the BNRF1 for ATPase activity. 
We could hypothesize that this might provide BNRF1 with an energy source for chromatin 
remodeling when it replaces the ATP-dependent chromatin remodeler ATRX. We prepared either 
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FLAG-vector or FLAG-BNRF1 transfected cell lysate, immunoprecipitated with FLAG-beads from 
transfected 293T cells (Figure 3.3F). Cell lysates (input) or FLAG-purified proteins were co-
incubated 1 hour in vitro with 32P- γ−ATP. Reactions were then analyzed by thin layer 
chromatography (TLC) (Figure 3.3D and E), on which released free phosphates migrate upward 
faster than ATP. We found that FLAG-BNRF1 released ~10 fold more free phosphates from ATP 
than FLAG alone. This suggests that BNRF1, like the ATP-dependent chromatin remodeler ATRX, 
may contain inherent or associated ATPase activity. However, we next tested several BNRF1 
mutants and obtained results that don’t support the statement that BNRF1 has inherent ATPase 
activity. The above assay was repeated with 293T cells transfected with BNRF1 mutant 
constructs Daxx-interaction domain (DID) and mutated putative ATPase domain (dA) (Figure 
3.3H). While WT-BNRF1 still released free phosphates, the DID and dA mutants did so, too 
(Figure 3.3G). This suggests that either DID contains an ATPase domain, or our FLAG 
purification co-purifies with an ATPase. 
 
3.8 WT BNRF1, but not the d26 or dATPase mutants, induce mobilization of core 
histone H3.3 
The observations that BNRF1 replaces ATRX from the Daxx-ATRX histone H3.3 loading 
complex suggest the possibility that BNRF1 may modulate the chromatin remodeling functions of 
Daxx, which should affect histone dynamics.  Global histone dynamics can be measured in living 
cells using fluorescence recovery after photobleaching (FRAP) with fluorescently tagged histone 
(Kimura, 2005).  We asked whether BNRF1 was sufficient to increase the pool of histone H3.3 
not bound in chromatin at any given time, and whether this mechanism was dependent on the 
Daxx interaction or the putative ATPase domain. We evaluated the kinetics of FRAP of GFP-H3.3 
(Conn et al., 2013), which is loaded onto chromatin by the Daxx-ATRX complex (Lewis et al., 
2010). Expression of WT BNRF1 was sufficient to induce a general mobilization of H3.3 away 
from chromatin (Figure 3.4A, compare red to green lines).  In contrast, this mobilization was not 
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observed with mutant BNRF1 or RFP not fused to any protein. GFP-H3.3 fluorescence signal 
recovery in the photobleached region was faster in cells expressing RFP-BNRF1 (Figure 3.4A, 
compared to green lines).  In contrast, fluorescence was not recovered any faster in cells 
expressing a Daxx-interaction-deficient mutant (BNRF1-d26), BNRF1 with a mutation in a 
putative ATPase domain (BNRF1-dATPase), or RFP vector only, than in cells not expressing 
detectable levels of any of these proteins.   
Mobilization of GFP-H3.3 in cells that co-expressed RFP-BNRF1 was next normalized to 
their mobilization in BNRF1-nonexpressing cells on the same coverslip. We then analyzed the 
relative fluorescence intensity of the photobleached nuclear region immediately after 
photobleaching, which reflects the pool of free histones. We found that BNRF1 was sufficient to 
increase the free pool of H3.3 by 34 +/- 10%  (p<0.01) (Figure 3.4B).  In contrast, the free pool of 
H3.3 showed no significant changes in d26, dATPase, or RFP vector -expressing cells.  
The slow exchange rate of H3.3 was also studied by analyzing the fluorescence recovery 
rate at the later times, 20-100 sec post photobleaching. H3.3 slow exchange rate was 90 +/- 43% 
greater in cells expressing detectable levels of WT BNRF1 than in those with no detectable 
BNRF1 (p<0.05).  In contrast, the rate was not greater in cells expressing detectable levels of d26, 
dATPase, or free RFP than in cells expressing detectable levels of only GFP-H3.3 (Figure 3.4C).  
However, the variability in the slow exchange rates did not allow reaching statistical significance 
when comparing WT versus mutant forms of BNRF1.  
Thus, WT BNRF1 is sufficient to mobilize histone H3.3, increasing their levels available in 
the free pools and augmenting H3.3 slow chromatin exchange rates. The Daxx-interaction-
deficient (d26) or ATRX-disruption-deficient (dATPase) mutants, in contrast, are unable to induce 
H3.3 mobilization. 
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3.9 Higher levels of viral gene expression during early infection in the absence 
of ATRX 
ATRX and Daxx has been associated with antiviral resistance in the form of repression of 
HSV1 and HCMV viral gene expression (Lukashchuk and Everett, 2010; Lukashchuk et al., 2008); 
while Daxx-ATRX loaded histone H3.3 has also been linked with gene repression of a CMV 
promoter-driven plasmid (Newhart et al., 2013b). We reasoned that the disruption targets of 
BNRF1, Daxx and ATRX, may repress EBV gene expression. We tested viral gene expression 
during EBV primary infection of cells with Daxx or ATRX knocked down.  For these shRNA 
depletion experiments, we utilized an EBV-negative Akata Burkitt lymphoma cell line, which could 
be selected after lentivirus shRNA infection, and subsequently infected with EBV to evaluate early 
events after primary infection.  EBV negative Akata B-cells were transduced with shRNA-
expressing lentivirus, targeting Daxx (shDaxx), ATRX (shATRX), and also a non-targeting shRNA 
(shNeg). Knockdown efficiencies are shown in Figure 3.5A. shRNA-expressing cells were then 
infected with EBV virus produced from BNRF1 null (∆BNRF1) bacmids (Feederle et al., 2006). 
Infected cells were harvested 72 hours post infection, and viral mRNA levels were analyzed by 
RT-qPCR (Figure 3.5B). When ATRX was knocked down (shATRX), there was a significant 
increase in viral latent gene expression levels (specifically EBNA2 and LMP2). While the effects 
of shATRX on BZLF1 expression were too small to reach statistical significance. Whereas 
knockdown of Daxx (shDaxx) did not show any difference from the negative control (shNeg). 
These results suggest that ATRX is a repressor of EBV pre-latent gene expression during primary 
infection and that BNRF1 is required to neutralize ATRX-mediated repression. 
 
3.10 BNRF1 siRNA-depleted virus fails to produce latent transcripts 
With BNRF1 forming an alternate complex with Daxx-histones and mobilizing histones, we 
aimed to study the effects of BNRF1 on viral chromatin assembly in the early establishment of 
EBV latent infection. Previous studies utilized a recombinant EBV with a truncation in the BNRF1 
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gene, which was characterized to be unable to express viral genes upon primary infection of B-
lymphocytes (Feederle et al., 2006).  To eliminate any concern that mutations in the viral DNA 
may alter chromatinization, we generated BNRF1 depleted virus using siRNA during viral 
production.  293 cells stably carrying the EBV genome bacmid were transfected with the EBV 
transactivator Zta and BALF4 to induce viral production. These virus production cells were also 
co-transfected with non-targeting (siCtrl) or BNRF1-targeting (siBNRF1) siRNA. The knockdown 
efficiency in virus producer cells is shown in Figure 3.5C. As only the protein but not the coding 
DNA of BNRF1 is repressed by siRNA, any phenotype of siBNRF1 is likely due to the lack of 
tegument-delivered, rather than de novo synthesized BNRF1, or any potential defect on the viral 
genome. We first tested the siBNRF1 virus infection system to evaluate if absence of BNRF1 
protein in the tegument also resulted in gene expression failure. Viruses that infected B cells in 
the absence of BNRF1 (siBNRF1) failed to express several latency-associated viral genes, 
including EBNA2, EBNA1, LMP1, and LMP2A (Figure 3.5D), as expected (Tsai et al., 2011). 
These results indicate that the absence of BNRF1 protein in the tegument results in a failure of 
viral gene expression during early infection. 
 
3.11 BNRF1 protein in early infection is primarily tegument-derived and persists 
up to 72 hours post infection.  
In order to test the effects of BNRF1 during early infection, we need to get a better 
understanding of the behavior of this viral gene and it’s protein product. Specifically, we asked 
two questions: First of all, for how long is tegument-delivered BNRF1 protein stable in the infected 
cells? Secondly, is tegument-delivered BNRF1 the sole source of BNRF1, or is it de novo 
expressed upon early infection? We thus infected primary B cells with the Mutu strain of wild type 
EBV, and collected infected cell in a time course for protein and mRNA analysis. We found by 
Western blot that BNRF1 protein is stable in infected cells up to 48 hours post infection (hpi), and 
then gradually decaying yet still easily detectable up to 96hpi (Figure 3.6A). This suggests that 
BNRF1 is present and may be supporting infection up to 3 to 4 days post infection. However, as 
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the BNRF1 band at 24hpi is slightly stronger then that of 6hpi. This could be resulting from virions 
in the media attached to the cell surface yet not entering until the time between 6-24hpi; or could 
be due to de novo produced BNRF1. To test the latter possibility, we tested Mutu-infected B cells 
for the presence of viral mRNA transcripts (Figure 3.6B). As controls, we tested the immediate 
early gene BZLF1, the latent genes EBNA2 and LMP2A, and late genes gB and gp350. In 
accordance with prior reports, we only detected the first expressed latent gene EBNA2, which 
was detectable as early as 8hpi. While all other genes including BNRF1 was not detectable up to 
96hpi. We conclude that during early infection, the majority of BNRF1 is tegument derived, and 
that BNRF1 is stable enough to persist through the first three days post infection. 
 
3.12 Tegument-delivered BNRF1 disperses Daxx/ATRX and prevents Daxx/ATRX 
from localizing next to viral DNA upon primary infection 
Biochemical protein interaction assays suggest that BNRF1 disassembles Daxx-ATRX. 
However, we have not shown direct evidence of BNRF1 disruption of Daxx-ATRX in primary 
infection. It was also unclear whether the siBNRF1 virus could deliver its genome into the host 
nucleus. We thus tested infection of primary B lymphocytes using virus produced in siBNRF1 or 
siCtrl-treated cells, and stained the infected cells for Daxx or ATRX and EBV viral DNA by 
Immunofluorescence coupled with Fluorescent in situ hybridization (IF-FISH) at the 72 hours post 
infection time point. Infected cells were stained with Daxx or ATRX antibodies (red signal) and 
then the viral genomes in situ hybridized with pre-labeled EBV viral DNA fragments (green signal). 
FISH signals were present in infected cell nuclei regardless of the presence or absence of 
BNRF1, indicating that genomes are delivered to the nucleus in the absence of BNRF1 (Figure 
3.7A-B). Furthermore, we found two phenotypes of ATRX and Daxx nuclear staining patterns 
(Figure 3.7): highly speckled nuclear bodies and less distinct foci with a highly dispersed 
background staining. Both speckled and dispersed patterns were expected regardless of infection 
conditions, as nuclear bodies were known to be disassembled during mitosis (Ishov et al., 2004). 
However, the dispersed patterns looked reminiscent of the dispersed ATRX foci in 293T cells 
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transiently transfected with FLAG-BNRF1 (Tsai et al., 2011), and was likely to be increased as a 
result of BNRF1-mediated disruption (Figure 3.7Aii, 3.7Bii). Indeed, there was a significant higher 
rate (71%) of dispersed ATRX pattern (Figure 3.7A) in infections in the presence of BNRF1 (siCtrl) 
than in the absence of BNRF1 (siBNRF1).  When the speckled versus dispersed patterns in 
infected cells (green FISH signal positive) were quantified (Figure 3.7C), we found a significantly 
higher rate (71%) of dispersed ATRX pattern (Figure 3.7A) in infections in the presence of 
BNRF1 (siCtrl) than in the absence of BNRF1 (siBNRF1, 38%) (Figure 3.7C). The rate of Daxx 
dispersion (Figure 3.7B-C) was also higher in siCtrl (73%) than in siBNRF1 (26%) -infected cells, 
as expected. These results suggest that tegument-delivered BNRF1 displaces both Daxx and 
ATRX during primary infection, likely preventing their transcriptional repression and anti-viral 
resistance activities. In the absence of BNRF1 (siBNRF1), we have also noticed an increase of 
viral DNA localizing right next to Daxx or ATRX foci (Figure 3.7Aiii, 3.7Biii, 3.7D), supporting the 
ChIP findings that BNRF1 prevents Daxx and ATRX association with viral chromatin. These data 
suggest that through spatial relocalization of Daxx and ATRX, tegument-delivered BNRF1 could 
disrupt Daxx-ATRX-mediated resistances in vivo during primary infection. 
 
3.13 BNRF1 prevents ATRX and H3.3 loading while promoting active chromatin 
marks on viral chromatin 
EBV viral DNA enters the cell devoid of histones, and H3.3 is the only histone H3 variant 
that is loaded independently of DNA replication (Ahmad and Henikoff, 2002). As Daxx selectively 
loads histone variant H3.3, we hypothesize that BNRF1-dependent disruption of Daxx-ATRX may 
prevent or regulate histone H3.3 loading on viral chromatin. We tested this model using chromatin 
immunoprecipitation (ChIP) assays on B lymphocytes infected with EBV in the presence (siCtrl) 
or absence of BNRF1 (siBNRF1). Infected human primary B cells were collected 72 hours post 
infection (72hpi) and cross-linked. At 72hpi, tegument-delivered BNRF1 is just starting to decay, 
while the first expressed latent gene EBNA2 has started to be expressed. Several EBV loci were 
tested, including a CTCF binding site next to the terminal repeats (CTCF 166), the first activated 
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latent promoter Wp, the immediate early promoter Zp, and a region in the EBNA2 gene body as 
an example of a region that is presumably less regulated.  H3.3 chromatin binding increased in 
cells infected with BNRF1-knockdown (siBNRF1) virus as compared to wild type (siCtrl) virus 
(Figure 3.8A, top two panels). We tested if the change in H3.3 loading was associated with 
changes in histone chaperone access to viral genome.  ATRX and Daxx binding on viral DNA 
was increased in the absence of BNRF1 (siBNRF1) (Figure 3.8B). H3.3, Daxx, and ATRX binding 
was elevated at most viral loci tested in the siBNRF1 virus infected cells. Of all sites tested, the 
most prominent enrichment of H3.3 was located at Wp, which is among the earliest activated viral 
promoters driving EBNA2 expression in the pre-latent phase (Tierney et al., 2000). 
H3.3 loading increased and viral gene expression was inhibited in siBNRF1 infected cells. 
However, H3.3 association with active or repressive chromatin appears to be genomic region and 
chaperone dependent. We thus further tested by ChIP, the presence of active (H3K4me3) and 
repressive (H3K9me3) chromatin markers on viral genomes during early infection (Figure 3.8B 
lower two panels). While no H3K9me3 was found on early infection viral genomes, we found 
more H3K4me3 active markers in cells infected in the presence of BNRF1 (siCtrl) then in the 
absence of BNRF1 (siBNRF1). To control for different levels of histone H3 on viral genomes in 
the two infection sets, we tested H3K4me3 and pan-histone H3 binding, alternatively analyzing 
the H3K4me3 ChIP levels normalized to total histone H3 levels in the same region (Figure 3.8C). 
The increased presence of H3K4me3 on viral control regions in cells infected with BNRF1-
knockdown (siBNRF1) virus as compared to wild type (siCtrl) virus was also evident in the 
normalized data. These results suggests that BNRF1, which disassociates ATRX from Daxx, 
inhibits the deposition of histone H3.3, increases the active marker H3K4me3 on the viral genome, 
and in turn, promotes the viral gene expression required for latency establishment during early 
infection. 
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3.14 Discussion 
 DNA viruses may require host chromatin regulatory processes to protect and regulate their 
genomes, yet these same host processes can form repressive chromatin that blocks viral gene 
expression. In this respect, chromatin remodeling processes becomes a critical point of conflict 
between host and virus.  Herpesvirus-encoded tegument proteins play a key role in regulating 
viral gene expression during early infection, typically targeting host intrinsic resistances such as 
PML-NBs.  Here, we find that the EBV-encoded tegument protein BNRF1 modulates viral 
chromatin assembly by altering the histone H3.3 chaperone complex of Daxx-ATRX. We find that 
BNRF1 replaces the histone co-chaperone ATRX to form a ternary complex of BNRF1, Daxx, and 
histone H3.3/H4 but not histone H3.1. Mutations in motifs conserved across 
gammaherpesviruses prevent BNRF1 from displacing ATRX from Daxx while retaining the Daxx-
interaction function. BNRF1 can mobilize and increase the free pool of histone H3.3, an activity 
that is lost in ATRX-disruption-deficient mutants. IF-FISH and ChIP assays on primary infection 
reveal that BNRF1 prevents Daxx/ATRX-mediated assembly of histone H3.3 and promotes more 
active histone marks at key regulatory elements in the viral genome. Taken together, these 
findings support a model whereby EBV tegument protein BNRF1 modulates a host histone 
chaperone complex to ensure the expression of essential viral latent genes.  These findings 
suggest that ATRX-associated chromatin assembly acts as an intrinsic anti-viral resistance that 
can be overcome and reprogrammed by tegument proteins like BNRF1to promote viral gene 
expression programs. 
 The chromatin-associated factors that BNRF1 targets have important functions in cellular 
gene regulation and genome maintenance.  Mutations in Daxx, ATRX, and H3.3 are found with 
high frequency in several human cancers (Jiao et al., 2011; Schwartzentruber et al., 2012). 
Mutations in these factors have been correlated with an increase in homologous recombination 
and the alternative lengthening of telomere (ALT) in these cancer cells (Heaphy et al., 2011). The 
histone variant H3.3 is assembled in a DNA replication-independent manner by the histone 
chaperones HIRA or Daxx-ATRX.  Loading of H3.3 by HIRA is associated with transcription 
69	  
	  
activity (Ahmad and Henikoff, 2002). On the other hand, loading of histone H3.3 by Daxx-ATRX is 
associated transcriptional repression, particularly at repetitive GC-rich telomeric repeats 
(Goldberg et al., 2010), pericentric DNA repeats (Drane et al., 2010), and a CMV promoter-driven 
transgene array (Newhart et al., 2013b).  Mutations in ATRX are also known to cause alpha-
globin thalassemias and X-linked mental retardation syndromes where the underlying 
pathogenesis has been linked to defective chromatin assembly at repetitive DNA (Clynes et al., 
2013).   
Daxx, ATRX, and H3.3 have also been implicated in the control of viral gene expression  
infection.  Herpesviral DNA in virions is devoid of histones (Gibson and Roizman, 1971) and is 
only loaded with histones after entry in the nucleus. For HSV-1, histone H3.3 is loaded on the 
viral genome immediately upon nuclear entry, and then replaced with histone H3.1 after initiation 
of viral DNA synthesis (Placek et al., 2009). For human CMV, Daxx silencing prior to infection 
resulted in a decrease of heterochromatic marks on the major viral immediate early promoter 
(MIEP) and increase of viral gene expression (Woodhall et al., 2006). Similarly, adenovirus (Ad5) 
encodes proteins that target ATRX degradation to prevent the assembly of H3.3 and 
transcriptional repression of essential viral genes (Schreiner et al., 2013).  Taken together, these 
reports suggest that Daxx-ATRX loading of H3.3 contributes to antiviral resistance by establishing 
repressive heterochromatin on viral genomes.  
The findings presented here indicate that BNRF1 prevents repressive chromatin formation 
onto the EBV genome during primary infection of B-lymphocytes.  Both ChIP and IF-FISH assays 
demonstrate that Daxx, ATRX, and histone H3.3 occupancy at the viral genome increases after 
infection with virus prepared from BNRF1 depleted cells (Figures 3.7 and 3.8). The BNRF1-
dependent decrease in H3.3 loading on the viral genome is consistent with the FRAP observation 
that BNRF1 increases the free pool of H3.3 (Figure 3.4B).  We also show that BNRF1-deficient 
virus can be partially rescued in host cells with ATRX depleted (Figure 3.5B).  Surprisingly, 
depletion of Daxx did not result in the rescue of BNRF1-deficient virus, suggesting that ATRX is 
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the limiting factor, or that Daxx and ATRX have non-redundant functions in viral gene regulation.  
Regardless, our findings suggest that ATRX is a principal restriction factor for EBV chromatin 
regulation during primary infection.  We propose that BNRF1 selectively replaces ATRX from the 
Daxx-H3.3/H4 complex to prevent the assembly of repressive H3.3 chromatin on the viral 
genome. 
The importance of BNRF1 to viral infection and gene expression is underscored by its 
evolutionarily conservation among all gammaherpesvirus family members. All known 
gammaherpesviruses contain a BNRF1 homologue found in the tegument, including KSHV 
ORF75, HVS ORF3, and MHV68 ORF75c (Figure 3.3A).  The homology is found exclusively in a 
domain that contains sequence homology to a cellular purine biosynthesis enzyme, 
phosphoribosylformylglycineamide amidotransferase (FGARAT), which hydrolyzes ATP to 
transfer an amino (NH2) group from glutamine to its substrate. The precise function of this 
FGARAT domain in viral proteins is not yet known. Nevertheless, we found that the conserved 
ATPase and glutamine amidotransferase (GATase1) domains are important for disrupting ATRX 
from the Daxx-histone complex (Figure 3.3C).  Furthermore, we have found that immunopurified 
BNRF1 co-purifies with ATPase activity (Figure 3.3D-E).  However, we cannot rule out that the 
ATPase activity is a result of an associated cellular protein, as follow up experiments with 
mutated BNRF1 still retained activity (Figure 3.3G). Further experiments with highly purified 
BNRF1 are required to elucidate this issue. 
All viral FGARAT family members target PML-NBs.  However, each of these proteins 
functions through different mechanisms of disrupting PML-NB function. The MHV68 ORF75c 
degrades PML (Ling et al., 2008), and HVS ORF3 degrades Sp100 (Full et al., 2012). Whereas 
KSHV ORF75 does not interact directly with Daxx, it has recently been found to relocate PML and 
Sp100 away from PML-NBs and likely degrades ATRX during both early infection and lytic 
reactivation in an endothelial cell line (Full et al., 2014). Notably, all reports of viral FGARAT-
induced protein degradations were investigated in epithelial model systems where 
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gammaherpesviruses preferentially undergo lytic replication shortly after infection.  In our study, 
we focused on the effects of EBV BNRF1 in B-lymphocytes, where a programmed latency is the 
predominant outcome. BNRF1 showed a non degradation-pathway of modifying Daxx-ATRX in 
these cells. Cell type dependencies were similarly observed for HCMV tegument protein pp71, 
which disrupted Daxx-mediated repression in differentiated cells supporting productive infection 
yet failed to prevent repression in undifferentiated cells where productive infection was not 
supported (Penkert and Kalejta, 2011; Saffert and Kalejta, 2007). Therefore, a comparison of 
BNRF1 function in lymphocytes versus epithelial cell types may shed light onto the mechanism 
whereby EBV enters latency or lytic replication cycles. 
In conclusion, we show that the host antiviral resistance orchestrated by Daxx, ATRX, and 
histone H3.3 can be altered by EBV tegument protein BNRF1. BNRF1 replaces ATRX in the 
Daxx-ATRX histone chaperone complex and can stimulate the global mobilization of histone H3.3.  
BNRF1 is essential for the early steps of viral infection as its absence results in increased Daxx, 
ATRX, and H3.3 binding on viral chromatin and shutdown of latent viral gene expression. BNRF1 
controls the process of viral chromatin assembly in preparation for the establishment of persistent 
latent infection by EBV.  These findings also demonstrate that host chromatin assembly is an 
important form of host cell intrinsic resistance to viral infection. 
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3.16 Figures 
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Figure 3.1. BNRF1 binds Daxx on its histone-binding domain (HBD) and co-
purifies with histone H3.3 
 (A) Diagram of HA-Daxx deletion constructs with functional domains indicated.  (B) 
Immunoprecipitation (IP) assay of FLAG-BNRF1 and HA-Daxx deletion constructs, visualized by 
Western blot. Input (6%) of each IP is shown in the left. (C) IP assay of Daxx and Daxx-HBD with 
or without BNRF1. (D) IP assay of FLAG-tagged histone H3.1 or H3.3 with Daxx and BNRF1, 
analyzed by Western blot.  
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Figure 3.2. Daxx-interaction-domain of BNRF1 binds the Daxx/H3.3/H4 complex 
(A) Diagram of GST-tagged BNRF1 Daxx-interaction-domain (DID) construct. (B) GST pull 
down of BNRF1-interacting nuclear proteins. Purified GST-BNRF1-DID or GST alone, was used 
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to pulldown proteins from Mutu I cell nuclear extract. Total nuclear extract (input) and eluted 
proteins were analyzed by Western blot; ATRX and poly-ADP ribose polymerase (PARP) probed 
as negative controls. (C) (i-iv) Gel filtration chromatograms of BNRF1-DID and Daxx/H3.3/H4 
complexes. Bacteria produced, purified BNRF1-DID, H3.3/H4 tetramer, and Daxx/H3.3/H4 
complex were passed through a Superdex S75 column in different combinations. (vi-x) Fractions 
were collected and analyzed by SDS-PAGE and Coomassie Blue staining. 
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Figure 3.3. FGARAT-homology domains of BNRF1 are essential for ATRX 
disruption yet not important for co-purified ATPase activity  
(A) Sequence comparisons of EBV BNRF1 with other homologous genes, including KSHV 
ORF75, MHV68 ORF75c, Human FGARAT, and Salmonella typhimurium PurL. Arrowheads 
denote residues on Salmonella PurL that form hydrogen bonds with ADP. (B) Diagram of FLAG-
BNRF1 constructs with deletions in FGARAT-homology conserved regions. (C) IP-Western assay 
of FLAG-tagged BNRF1 FGARAT-homology mutants in transfected 293T cells and probed for 
association with Daxx and ATRX. (D) ATPase assay of purified FLAG peptide or FLAG-BNRF1 
protein. Protein samples were co-incubated with 32P-g-ATP, and then analyzed by thin layer 
chromatography (TLC) for visualization of gamma phosphate release. (E) Band intensities 
analysis of TLC plate band. Percent ATP conversion calculated by dividing free phosphate band 
(Pi) intensities by the total intensity of Pi + ATP. (F) Proteins used for ATPase assay in Figure 
3.3A analyzed by Western blot, probed with anti-BNRF1 antibody. (G) ATPase assay of FLAG 
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peptide (V) and WT-BNRF1 (B), along with BNRF1-Daxx interaction domain (DID, as Figure 2.2A) 
and BNRF1 with a mutation in a putative ATPase domain (dA, as Figure 3.3A-B). (H) Western 
blot of FLAG-purified proteins for ATPase assay in Figure 3.3G, probed with anti-FLAG antibody. 
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Figure 3.4. WT BNRF1 mobilizes Histone H3.3, whereas d26 or dATPase mutants 
do not 
(A) Fluorescence recovery after photobleaching (FRAP) of histone H3.3 in cells expressing 
detectable levels of RFP-BNRF1 compared with cells with no detectable RFP signal.  Line graphs 
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present the relative normalized fluorescence intensity of the photobleached nuclear region plotted 
against time; average +/- SEM.  Signal readouts from cells that co-expressed detectable levels of 
GFP-H3.3 and WT, d26, or dATPase RFP-BNRF1, or free RFP where shown in red lines; signal 
from cells that expressed detectable levels of only GFP-H3.3 shown in green. (B) Bar graphs 
presenting the free pool of GFP-H3.3 in cells expressing detectable levels of WT, d26, or 
dATPase RFP-BNRF1, or free RFP, relative to the levels in cells expressing detectable levels of 
only GFP-H3.3 on the same coverslip; average +/- SEM; * p < 0.05; ** p < 0.01. (C) Average slow 
GFP-H3.3 exchange rate in cells expressing detectable levels of WT, d26, or dATPase RFP-
BNRF1, or free RFP, relative to cells expressing detectable levels of only GFP-H3.3 on the same 
coverslip; average +/- SEM; * p < 0.05; ** p < 0.01. 
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Figure 3.5. Viral gene expression in the pre-latent phase is repressed by ATRX in 
the absence of BNRF1. 
(A) Western blot validation of shRNA-mediated Daxx or ATRX depletion in EBV-negative 
Akata cells, with non-targeting shNeg as a negative control. (B) qPCR assay of viral gene 
expression in Daxx/ATRX-depleted EBV-infected cells. EBV-negative Akata cells with Daxx or 
ATRX depleted were infected with BNRF1-null virus and collected 48hpi for qRT-PCR 
quantification of mRNA levels. ** indicates statistical significance of p < 0.01, by one-tailed 
Student's T test; error bars, SD. (C) Confirmation of BNRF1 depletion in virus producer 293 cells 
by Western blot. Wildtype or BNRF1-deficient virus was collected from EBV genome-stabily 
transfected 293 producer cells, treated with control (siCtrl) or BNRF1-specific siRNA (siBNRF1). 
This batch of virus was used for the ChIP assays in Figure 3.8A. (D) qPCR assay of latent viral 
gene expression in siCtrl or siBNRF1 EBV-infected primary B lymphocytes collected 72hpi. 
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Figure 3.6. Tegument-derived BNRF1 is stable during early infection up to 3 days 
post infection while no de novo expression of BNRF1 could be detected. 
EBV-infected primary B lymphocytes in the pre-latent phase were collected in a time course 
and subject to (A) Western blot analysis of BNRF1 protein, and (B) qPCR assay of viral gene 
transcripts; error bars, SD. 
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Figure 3.7. BNRF1-depleted virus infection showed less Daxx/ATRX dispersion 
and more viral DNA located next to Daxx/ATRX foci. 
siCtrl, siBNRF1 EBV-infected or mock -infected primary B lymphocytes in the pre-latent 
phase (72hpi) were subject to IF-FISH to visualize the infecting viral DNA in green, in conjunction 
with ATRX (A) or Daxx (B) in red. Cell nuclei were visualized with the blue DNA stain, DAPI. In 
siBNRF1 infections, arrowheads indicates where viral DNA is localizing adjacent to ATRX (Aiii) or 
Daxx  (Biii) foci, insets showing zoomed-in views of the adjacent event. (C) Bar graph showing 
percent of infected cells (green positive) with dispersed (high nuclear background red signals with 
weak foci) ATRX or Daxx signals. (D) Percent of infected cells with ATRX or Daxx adjacent to 
viral DNA (red foci next to green foci). Approx. 60-100 infected cells counted per slide. Statistical 
significance tested by one-tailed Student's T test; error bars, SD. 
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Figure 3.8. BNRF1 decreases histone H3.3, Daxx, ATRX binding; and promotes 
H3K4me3 accumulation on viral genomic regions. 
BNRF1-depleted EBV-infected primary B lymphocytes in the pre-latent phase were tested 
for histone H3.3, Daxx, and ATRX binding on viral DNA. Human Primary B lymphocytes infected 
with siCtrl or siBNRF1-treated cell-produced virus were collected 72hrs post infection (hpi) and 
subject to chromatin immunoprecipitation (ChIP) to test for H3.3, H3K4me3, H3K9me3 (A), and 
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Daxx or ATRX (B) binding on viral genomic regions by qPCR. Regions tested include a CTCF 
binding site close to the terminal repeats (CTCF 166), the W promoter (Wp) which drives EBNA2 
expression in the pre-latency phase, the Z promoter (Zp) which drives the immediate early gene 
Zta, and a region in the EBNA2 gene body. Error bars, SD. (C) Bar graph of ChIP signals of 
H3K4me3 or pan H3 on siCtrl or siBNRF1 virus infected primary B cells, normalized to Pan H3 
values. 
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4. Materials and Methods 
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4.1 Ethics statement 
Human B-lymphocytes were obtained from the Wistar Institute phlebotomy lab. All samples 
were from anonymous adult donors and approved by the Wistar Institute Institutional Review 
Board. Written informed consent was provided by study participants. 
 
4.2 Cells 
Hep2 and 293T cells were grown in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10-11% fetal bovine serum (FBS, Atlanta Biologicals), 20 mM GlutaMAX 
(Gibco), 100 U/ml penicillin and 100 µl/ml streptomycin. 293HEK cells were grown in minimum 
essential medium Eagle (MEM), supplemented with 10% FBS and 20 mM GlutaMAX (Gibco). 
DG75 and Mutu I cells are EBV negative and positive (respectively) Burkitt's lymphoma cell lines, 
grown in RPMI 1640 medium (Mediatech Corning) supplemented with 10% FBS, 100 U/ml 
penicillin and 100 µl/ml streptomycin. EBV-negative Akata cells were grown in RPMI 1640 
medium supplemented with 11% FBS. African green monkey (Vero) cells were maintained in 
DMEM with 5% FBS.  Peripheral blood mononuclear cells (PBMCs) were isolated from fresh 
donated human blood by density gradient centrifugation with Ficoll-Paque Plus purchased from 
GE healthcare. Primary B cells were then isolated from PBMCs using Dynabeads Untouched 
Human B Cell isolation kit (Invitrogen) or EasySep Human B cell enrichment kit (Stemcell 
Technologies). Stable 293 cell lines expressing FLAG-BNRF1 (clone 3 and clone 9) and empty 
FLAG vector (clone C) were grown in DMEM as described for 293T cells above, supplemented 
with 2.5 µg/ml Puromycin for selection. All cells were grown in a 5% CO2 incubator at 37°C. 
 
4.3 Viruses bacmids and virus production cells 
Bacmid-sourced viruses were produced using chloramphenicol and hygromycin resistant 
bacmids containing the EBV genome and the gene coding for green fluorescence protein (GFP). 
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293/EBV-wt cells (a gift from H. J. Delecluse) are 293HEK cells stably transfected with the wild 
type EBV bacmid (Delecluse et al., 1998). 293/△BNRF1 cells (a gift from H. J. Delecluse) are 
293HEK cells stably transfected with an EBV bacmid with the BNRF1 gene deleted (Feederle et 
al., 2006). 293/EBV-wt and 293/△BNRF1 cells were grown in DMEM or RPMI 1640 medium 
supplemented with 10% FBS and 100 µg/ml hygromycin to ensure bacmid retention. 
 
4.4 Enzymes and antibodies 
All restriction enzymes, T4 DNA ligase and associated buffers were purchased from New 
England Biolabs. Monoclonal mouse anti-FLAG antibody (F1804), Polyclonal rabbit anti-FLAG 
anibody (F7425), Polyclonal rabbit anti-Daxx antibody (F7810), Monoclonal Anti-α-Tubulin 
antibody (T5168), Monoclonal mouse anti-β-Actin-Peroxidase antibody (A3854), and Anti-mouse 
IgG R-Phycoerythrin (PE) conjugated antibody (P8547) were purchased from Sigma-Aldrich. 
Monoclonal mice anti-PML (PG-M3, sc-966), polyclonal rabbit anti-ATRX (H-300, sc-15408), and 
polyclonal rabbit anti-ZEB1 (sc25388), and non-specific rabbit IgG (sc-2027) were purchased 
from Santa Cruz Biotechnology. Mouse anti-HA-tag (6E2) and Rabbit anti-GST (91G1) antibodies 
were purchased from Cell Signaling Technology. Rabbit anti-histones H3.3 (09-838), pan H3 (07-
690), H3K4me3 (07-473), and mouse anti-EA-D antibody were purchased from Millipore. Rabbit 
serum anti-H3K9me3 (39161) were from Active Motif.  Rabbit anti-Sp100 (AB1380) was 
purchased from Chemicon International. Polyclonal rabbit anti-PARP1 antibody (ALX-210-895-
R100) was purchased from Enzo Life Sciences. Anti-EBV-VCA (0231) antibody was purchased 
from Pierce Thermo Scientific.  
Rabbit polyclonal anti-BNRF1 was custom produced by YenZym Antibodies, LLC. 
Antibodies were raised against the C-terminal 1296-1318aa peptide of BNRF1: N’-
SPWTLMFQAAHLWSLRHGRPSE-C’ in rabbits. Antiseurm from 1st and 2nd bleed from rabbits 
YZ2259 & YZ2260 were affinity purified, and tested by Western blot on cell lysates from Zta 
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induced EBV bacmid production cells (induced as section 4.10): with wildtype EBV bacmid (WT), 
or 293/△BNRF1 complemented with FLAG-vector or FLAG-BNRF1. Validation Western blot as 
Figure 4.1. 
 
4.5 Plasmids 
BNRF1 was cloned into the HindIII-SalI sites of the p3xFLAG-Myc-CMV-24 Expression 
Vector (Sigma-Aldrich), using the PCR primers: gcgaagcttgaagagaggggcagggaaacgcaa and 
gcggtcgactcactcggaggggcgaccgtgcctg. BNRF1 deletion mutants were generated by site directed 
mutagenesis as follows. PCR Primers (Table 4.1-4.4) were designed so that the front and rear 
halves of the DNA oligo each binds the 5′ or 3′ regions flanking the targeted deletion site on the 
BNRF1 template. PCR reactions were setup using iProof High-Fidelity DNA polymerase 2x 
master mix (Bio-Rad), with primers at 1 µM concentration, and the FLAG-BNRF1 expression 
plasmid as the template at a concentration of 50 ng DNA in a 25 µl reaction setup. PCR was 
done with a Bio-Rad C1000 thermal cycler, thermal cycles setup according to DNA polymerase 
mix manufacturer suggested conditions. To clear out the wild type BNRF1 template, 15 µl of the 
PCR product were treated with 30 U DpnI (New England Biolabs) in a 20 µl reaction for 2 hours 
to over night at 37°C. 2 µl of DpnI-treated DNA were then transformed into 50 µl of Library 
Efficiency DH5α competent cells (Invitrogen). Colonies were screened for the deletion by enzyme 
digestion analysis of miniprep DNA, and then confirmed by DNA sequencing of the expected 
deletion site. 
pcDNA3-HA-Daxx was a generous gift from Dr. Hsiu-Ming Shih (Lin and Shih, 2002). Daxx 
and BNRF1-FGARAT domain deletions were produced by site-directed mutagenesis as done 
with BNRF1. For the FGARAT domain deletions, each truncation was replaced with a HindIII 
digestion site to aid with identification of correctly truncated constructs.  The Daxx-interaction 
domain (DID) region (360-600aa) of BNRF1 was cloned into the Not I and Sal I sites of a pRSF-
GST vector.  pRUTH5-Daxx-HBD(183-398aa), and bacterial expression vectors of H3.3 and H4 
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are kind gifts from Dr. Dinshaw Patel, as described previously (Elsässer et al., 2012). For FRAP 
assays, the BNRF1 (WT and mutants) coding sequence was cloned into the HindIII-SalI sites of 
the pCMV-mCherry-C3 expression vector. The plasmids encoding EGFP-H2B (Conn et al., 2011) 
and EGFP-H3.3 (a generous gift from Dr. John Th’ng, Northern Ontario School of Medicine) were 
constructed as described (Conn et al., 2013). 
 
4.6 Small interfereing RNAs (siRNAs) 
All siRNAs were purchased from Dharmacon Thermo Scientific. siCtrl is ON-TARGETplus 
Non-targeting siRNA #1 D-001810-01-05. BNRF1-targeting siRNAs are custom designed with 
Dharmacon’s online design tool, including one with a target sequence inside the open reading 
frame (sequence CGAGCAAGGUCCAGAUCAAUU), and one targeting the 3’-UTR (sequence 
CAAUAAACCCAAUGUGCAAUU). Daxx siRNAs include ON-TARGETplus siRNA Human DAXX 
J-004420-05-0010, and J-004420-06-0010. 
 
4.7 Immunoprecipitation assays 
BNRF1 expression plasmids were transfected using Lipofectamine 2000 (Invitrogen) 
according to manufacturer instructions. Cells were harvested 2 days post transfection by washing 
cells off the plate with PBS. Harvested cells were further washed 3 times with cold PBS, and then 
subject to lysis with freshly prepared NET lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 
mM EDTA, 0.5% NP-40, and 0.1% mammalian protease inhibitor cocktail mix (P8340, Sigma-
Aldrich), at 1 ml NET per IP pull-down. Cell lysates were homogenized by doing 10 strokes in a 
Dounce homogenizer. 60 µl of each lysate were isolated after this step as input control. The 
remaining lysates were incubated at 4°C rotating for 30 mins to fully solubilize proteins. Lysates 
were then spun at 13000 rpm 5 mins to remove insoluble cell debris, then antibodies were added 
(5 µl of each antibody per IP) to the cleared lysates, and left rotating over night. 100 µl of 50% 
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slurry of Protein A sepharose beads (GE healthcare) in NET buffer was added to each IP with 
rotating at 4°C for 2–3 hours, then washed three times with NET for 10 mins (rotating at 4°C) per 
wash. Pulled down proteins were released by adding 50 µl 2x Laemmli buffer (100 mM Tris-Cl pH 
6.8, 4% SDS, 0.2% Bromophenol Blue, 20% Glycerol), and boiling for 10 mins at 100°C. The 
resulting samples (excluding beads) were then loaded directly into protein gels and subject to 
Western blot analysis. 
For mass spectrometry identification of BNRF1 associated proteins, FLAG-BNRF1 
expressing and FLAG-vector control stable cell lines were generated as mentioned above. 
Nuclear extracts from 5×107 cells were subject to immunopurification with anti-FLAG Sepharose 
beads (A2220, Sigma-Aldrich) followed extensive washing with NET buffer, and FLAG peptide 
elution. Eluted protein was subject to precipitation with 10% trichloroacetic acid (TCA) followed by 
SDS-PAGE and colloidal blue staining. Sections of the gel with enriched polypeptides were 
subject to LC/MS/MS at the Wistar Proteomics Facility. 
For Daxx-histone interactions, the IP was performed as above with minor modifications. 
After adding NaCl to extract nuclear proteins, samples were sonicated 30s on 1min off for 5mins 
to clear genomic DNA, then pre-cleared for 2hrs with 50µl (per IP) of 50% slurry Protein A beads. 
Lysates were centrifuged for 2mins 3000rpm at 4°C to remove beads and debris. 4µg/IP of 
antibodies or 25µl FLAG-beads (Sigma A2220) were incubated overnight. 
 
4.8 Immunofluorescence microscopy 
Hep2 cells were transfected with BNRF1 expression plasmids using Lipofectamine 2000 
(Invitrogen) according to the manufacturer's instructions, transfected cells were then reseeded at 
2.7×104 cells/well in 24 well plates containing microscope coverslips 5 hours post transfection. 2 
days post transfection, coverslips with cells attached were harvested, fixed with 1% 
paraformaldehyde at room temperature for 15 mins, then permeablized with 0.3% Triton-X 100. 
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Coverslips were then stained with the first antibodies over night at 4°C. First antibody dilutions 
used were as follows: mouse anti-FLAG at 1:20000, rabbit anti-Daxx at 1:5000, rabbit anti-FLAG 
at 1:5000, mouse anti-PML at 1:250, rabbit anti-ATRX at 1:250, rabbit anti-Sp100 at 1:800, all 
antibodies diluted in PBS. Second antibody stainings were carried out for 1 hour at room 
temperature with the red-fluorescent Alexafluor594 goat anti-rabbit antibody and green 
Alexafluor488 goat anti-mouse antibody (both from Invitrogen) each at 1/800 dilution in PBS. 
Coverslips were washed twice in PBS for 5 mins between each of the above treatments. Cell 
nuclei were stained briefly with DAPI (diluted to a final concentration of 0.167 µg/ml in PBS) for 2 
mins, then washed with PBS, 70% EtOH, then 100% EtOH to wash out residual salts. Coverslips 
were air-dried briefly, and then mounted onto microscope slides with Vectasheld mounting media 
(Vector Laboratories). Mounted slides were examined under a Nikon E600 upright microscope 
with a 100x oil objective. Photos for nuclear body quantification were took using a 40x objective to 
maximize the number of cells in each photo while retaining a clear view of PML bodies. 
 
4.9 Nuclear body quantification 
Microscopy photos were analyzed using ImagePro Plus 6.2 software (Media Cybernetics). 
Photos were pre-processed by subtracting out the background intensity using the operation 
function (with a value of −30), and passing through a flatten filter (a value of 10). A morphological 
‘top hat’ filter was then applied to emphasize points or grains brighter then the background. The 
number of nuclear bodies in each cell nucleus was counted by quantifying the object numbers 
after applying the signal intensity threshold/segmentation tool to select the nuclear bodies as 
objects. Cell boundaries were defined by the outline from DAPI channel photos of the same field, 
while omitting all cells on the border of the image border. Resulting quantification numbers were 
then analyzed using Prism 4 software (Graph Pad Software), statistical analysis did by Mann-
Whitney U non-parametric, unpaired t test. 
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4.10 Subcellular fractionation assay 
293T cells were transfected in 10 cm plates with 2 µg expression plasmids of either empty 
FLAG vector, WT-BNRF1, BNRF1-DID, or 6 µg of BNRF1-d26. Transfection was carried out 
using 10 µl Lipofectamine 2000 (Invitrogen) per transfection, following manufacturer instructions. 
Cells were harvested 24 hrs post transfection. 1/6 of cells isolated as input control. The rest of the 
cell pellets were fractionated with the Fermentas ProteoJET Cytoplasmic and Nuclear Protein 
Extraction Kit (K0311). The resulting cytoplasmic and nuclear fractions, along with the input 
samples, were analyzed by Western blot. 
 
4.11 BNRF1 complementation virus infection assay 
To induce lytic virus production, 293/EBV-wt and 293/△BNRF1 cells were transfected in 10 
cm plates with expression plasmids of 1.75 µg BALF4, 3.25 µg BZLF1 or cDNA3 empty vector, 
and 3 µg of either empty FLAG vector or 3 µg BNRF1 or 7.5 µg BNRF1-d26. Transfection was 
carried out using 15 µl Lipofectamine 2000 (Invitrogen) per transfection, following manufacturer 
instructions. The media of virus production cells were harvested 3 days post transfection, filtered 
through 0.45 µm filters, and added directly to freshly isolated primary B cells. B cells in virus 
containing media were centrifuged for 1200 rpm 90 mins at 25°C to enhance infection. 
For measuring infection by GFP levels, infected B cells were treated with 1 mM Sodium 
Butyrate and 20 ng/ml TPA 3 days post transfection to enhance GFP expression, and the number 
of GFP positive cells in each well were counted manually under a Nikon TE2000 microscope 
using a 20x objective. 
For measuring virus gene expression in infected B cells, cells were collected 4 days post 
transfection, and total RNA was purified using Trizol (Invitrogen). The resulting RNA was then 
subject to DNase 1 treatment at 2 U/50 µl, 1 hour at 37°C, then DNase was heat inactivated by 
adding a final concentration of 5 mM EDTA and incubated at 70°C for 10 mins. cDNA was 
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synthesized using the Super Script III first strand synthesis system reverse-transcription kit 
(Invitrogen). The resulting cDNA was then subject to real time PCR analysis by ΔCt method and 
normalized to viral titers, measured as described below. Real time PCR primers used are listed in 
Table 4.5 
To measure the amount of complemented BNRF1 protein that were packaged into virions, △BNRF1 virions complemented with WT-BNRF1, BNRF1-d26, or un-complemented, were 
produced as mentioned above. 100 µl of the harvested and filtered virus-containing media were 
isolated for viral titer measurement as described below. The rest of the virus-containing media 
were concentrated by loading the media above a 5 ml layer of 22.5% sucrose in PBS, then 
centrifuged at 27000 rpm (~100,000 g) 4°C for 1 hour in a SureSpin 630 Rotor (Thermo Scientific) 
with a Sorvall WX 100 Ultra ultracentrifuge. The resulting virus pellet was then resuspended in 
PBS, and analyzed by Western blot. Protein gel loading volumes were normalized according to 
viral titers to ensure equal amounts of virion protein in each well. 
 
4.12 EBV virus titer measure by real time PCR detection of DNA copy number 
EBV viral DNA in media was extracted as described by C. Busse et al. (Busse et al., 2010). 
Virus-containing media were treated with 5 U/50 µl of DNase I (New England Biolabs) for 1 hour 
at 37°C. DNase was then deactivated by adding EDTA to a final concentration of 5 mM, followed 
by 10 mins heat inactivation at 70°C. Samples were then mixed 1:1 with 0.1 mg/ml of proteinase 
K in water, and incubated at 50°C for 1 hour, followed by 20 mins of heat inactivation at 75°C. 
The released viral DNA was measured by real time PCR analysis, using a serial dilution series of 
Namalwa cell lysate as the standard curve, which contain two copies of integrated EBV genome 
per Namalwa cell. EBV genomes were detected using primers specific to the OriLyt region: 5′- 
CGTCTTACTGCCCAGCCTACTC-3′ (OriLyt-fwd), 5′- AGTGGGAGGGCAGGAAATG-3′ (OriLyt-
rev). 
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4.13 Virus gene expression assay on bacmid/BNRF1 co-transfected cells 
Wild type EBV genome bacmids were prepared from 2.5 mls overnight LB culture using the 
Bacmax DNA purification kit (Epicentre). 293HEK cells were seeded (2.3 million cells per plate) 
the previous day in 10 cm plates, and transfected with 1.5 µg freshly prepared bacmids along 
with 0.5 µg of either empty FLAG vector, BNRF1, or BNRF1-d26 mutant. Transfection was 
carried out using Effectene transfection reagents (Qiagen), following manufacturer instructions. 
Cells were harvested three days post transfection, total RNA was purified using Trizol (Invitrogen), 
and then subject to DNase 1 treatment at 2 U/50 µl, 1 hour at 37°C. DNase was heat inactivated 
by adding a final concentration of 5 mM EDTA and incubated at 70°C for 10 mins. cDNA was 
then synthesized using the Super Script III first strand synthesis system reverse-transcription kit 
(Invitrogen). The resulting cDNA was then subject to real time PCR analysis by ΔCt method. Real 
time PCR primers used are listed in Table 4.5 
 
4.14 HSV-1 infection test on BNRF1-stable cell lines 
293T cells constitutively expressing empty vector (control cells) or FLAG-BNRF1 (BNRF1+ 
cells) were seeded the day before infection at 2 million cells per well in 24 well plates with 0.5ml 
DMEM per well. Test infection with wild type (KOS strain) or ICP0-deficient HSV (strain 7134), 
and subsequent qPCR analysis was done as previously described (Placek et al., 2009). Cells 
were incubated with virus diluted to the desired pfu in serum-free media for one hour, the virus 
containing media was then removed and fresh media was added back to the cells. Infected cells 
were collected at time points 1, 3, 6, 10, and 23 hours post infection (hpi). Mock infected cells 
were also collected at 1hpi. The total DNA of infected cells were extracted using the QIAamp 
DNA Blood Mini kit (QIAGEN #51104), then eluted with 200µl buffer AE. Extracted DNA were 
subject to real time PCR detection for cellular p21 as an internal control and the promotor region 
of HSV Thymidine Kinase (TKp) to quantify viral DNA. DNA copy numbers were analyzed by the 
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2-ΔΔCт method (34), as fold change over mock infected cells normalized to cellular p21 signal 
levels. 
4.15 shRNA-mediated knockdown of genes 
shNeg (pLKO-shNeg), shDaxx (pLKO-shDaxx-2) and shATRX (pLKO-shATRX90) 
constructs in lentivirus production plasmid backbones were generous gifts from Roger Everett. 
shNeg (sequence TTATCGCGCATATCACGCG) was designed to poorly target the E.coli DNA 
polymerase and extensively screened to ensure that it does not affect human nor viral transcripts. 
Use of shDaxx and shATRX was previously described else where (Lukashchuk and Everett, 2010; 
Lukashchuk et al., 2008). shZEB1.1 was obtained from the TRC library (Sigma, Inc), with 
targeting sequence GCAACAATACAAGAGGTTAAACTCGAGTTTAACCTCTTGTATTGTTGC). 
Mutu I cells were infected with lentiviruses carrying pLKO.1-puro vectors by spin-infection at 400 
g for 45 minutes at room temperature. The pellets were resuspended in fresh medium and left 
growing overnight. The RPMI medium was replaced each day, with 2.5 ug/ml Puromycin added 
for selection for lentivirus-transduced cells. The cells were collected after 9 days of puromycin 
selection, and subject to Flow cytometry quantification of EBV viral capsid antigen positive cells, 
and Western blot analysis. 
 
4.16 GST pulldown assays 
GST-BNRF1 DID protein was produced in E. coli., which was subsequently purified with 
Glutathione Sepharose 4B (Amersham) and dialyzed into binding buffer (150mM KCl, 0.01M Tris-
HCl pH7.5, 10% Glycerol, 0.5mM EDTA, 1mM DTT, 1mM PMSF). Dignam nuclear extracts were 
prepared from 9x106 Mutu I cells (46). For the pulldown assay GST-BNRF1-DID was pre-bound 
to glutathione beads, incubated with Dignam nuclear extracts overnight 4°C, and then washed 
four times in TEK150 buffer (20mM Tris pH7.5, 150mM KCl, 0.1mM EDTA, 1mM DTT, 1mM 
PMSF).  Proteins were eluted by boiling directly in Laemlli buffer, then analyzed by Western blot. 
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4.17 Size exclusion chromatography 
GST-BNRF1-DID 360-600aa, His-tagged Daxx 183-398aa, His-tagged H3.3, and His-tagged 
H4 were expressed in E. coli. GST-BNRF1 360-600aa was purified as a soluble protein in 0.5M 
NaCl, 20mM HEPES, 0.1mM TCEP, pH 8.0 using glutathione sepharose. The tag was removed 
with TEV protease and the BNRF1 was purified by ion exchange followed by gel filtration 
chromatography using a Superdex S75 column. Daxx, H3.3, and H4 were purified from inclusion 
bodies as described previously (Luger et al., 1999).  Purified Daxx, H3.3, and H4 (or only H3.3 
and H4) were mixed at an equimolar ratio in 8M Urea and dialyzed against 3.5M Urea and then 
extensively against 1.0M NaCl, 20mM HEPES, 0.1mM TCEP, pH 7.5. We were unable to purify 
Daxx alone as a soluble protein. The complexes were then purified by ion exchange 
chromatography and gel filtration. Purified BNRF1 was then mixed with Daxx/H3.3/H4 or H3.3/H4 
at an equimolar ratio in 1.0M NaCl, 20mM HEPES, 0.1mM TCEP, pH7.5 and loaded onto a 
Superdex 200 column equilibrated with the same buffer. 
	  
4.18 ATPase activity assay by thin layer chromatography 
To produce BNRF1 protein, 293T cells were seeded at 3 million cells per plate in 10cm 
plates and transfected with either empty FLAG vector or FLAG-BNRF1 the next day. Four plates 
of cells were used for each plasmid. Transfection was carried out using 4µg plasmid DNA and 10 
µl Lipofectamine 2000 (Invitrogen) per plate, each diluted in 500µl OPTI-MEM media (Invitrogen), 
following manufacturer instructions. Cells were harvested 72 hrs post transfection, and subject to 
immunoprecipitation as in section 4.6 with modifications using 25µl FLAG-beads (Sigma A2220) 
per million cells. The third wash after FLAG-bead binding was done in a buffer consisting of 
20mM Tris-HCl pH7.5, 20% glycerol, 100mM KCl, 0.2mM EDTA, 10mM beta-mercaptolethanol, 
PMSF and protease inhibitors. 1ml of the third wash buffer was then supplemented with 150µg of 
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3xFLAG peptide (Sigma) to produce an elution buffer. Pulldown beads from the four replicates of 
each plasmid transfection was pooled into a column and eluted with 400µl of FLAG-peptide-
containing elution buffer, with beads and elution buffer co-incubated for 30mins before collecting 
elutes. 
The ATPase enzymatic reaction was setup as thus. A reaction buffer was prepared with 
20mM Tris-HCl pH7.5, 100mM KCl, 0.2mM EDTA. Then reactions of 15µl volume were prepared 
with 4.2µl reaction buffer, 2µl gamma-P32 ATP, 0.8µl of 25mM MgCl2, and either 8µl sample or 
2µl sample diluted with 6µl buffer. Samples tested include pre-pulldown cell lysates (input) and 
FLAG-elution samples. Reactions were left to proceed at 37℃ for 1 hour. 6µl of each reaction 
sample were dotted onto a thin layer chromatography (TLC) plate (Pre-coated TLC-sheets 
POLYGRAM CEL 300 PEI/UV254 with 0.1mm cellulose MN300 polyethyleneimine coating, 
Macherey-Nagel 801 063) and left in a tank of 0.3M KH2PO4 pH3.5 to run for 2hrs. Resulting 
TLC plate was imaged by exposing a phospho-storage screen (GE healthcare) and scanned with 
a Typhoon phospho-scanner (GE healthcare) with the best sensitivity, 100dpi settings. 
	  
4.19 Analysis of H3.3 dynamics by fluorescence recovery after photobleaching 
(FRAP) 
Cells were transfected as described (Conn et al., 2008), with the following modifications: 
2.2-2.4x105 Vero cells were transfected with 6µl of Lipofectamine 2000 (Invitrogen), 6-8 µg GFP-
histone plasmids, and 5 µg of Cherry-BNRF1 (WT or d26 or dATPase mutants) or Cherry-C3 
plasmids. After 6.5 hrs incubation with the transfection mix, 1 ml of DMEM pre-warmed to 37˚C 
was added to the cells.  Cells were seeded onto coverslips the following day and analyzed at 
least 4hrs later.  The bulk of GFP-Histone H3.3 is incorporated into chromatin at this time (Conn 
et al., 2013).  Histone mobilization was evaluated by FRAP as described (Conn et al., 2008).  
Fluorescence within the photobleached region was normalized to total nuclear fluorescence, and 
expressed relative to the normalized fluorescence of the same region before photobleaching, to 
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account for differences between GFP-H3.3 expression levels between cells.  Relative free pool 
and slow exchange rate were obtained by expressing the relative fluorescence intensity of cells 
expressing detectable levels of WT, d26, or dATPase RFP-BNRF1 or free RFP as a ratio to that 
of cells not expressing detectable levels on each coverslip.  More than 15 cells per treatment from 
at least three independent experiments were quantitated. Statistical significance was tested using 
one-tailed Student’s T test.   
	  
4.20 Primary infection for testing pre-latent stage events 
For time course studies, Mutu virus was generated by culturing Mutu I cells in a 
concentration of 0.5 million cells/ml in 50-60ml RPMI with 50% spent media, 50% fresh media. 
The culture media was supplemented with 1mM Sodium Butyrate and 20µg/ml 12-O-
tetradecanoylphorbol-13-acetate (TPA) to induce viral production. For BNRF1 knockdown IF-
FISH and ChIP studies, siCtrl and siBNRF1 virus was induced by co-transfecting 293/EBV-wt 
cells in 60mm dishes with expression plasmids of 0.75 µg BALF4, 1.5 µg BZLF1, 5 µl of 40µM 
siRNA, and 5µl per plate of DharmaFECT Duo reagent (Thermo Scientific) according to 
manufacturer instructions. All virus-containing supernatants were collected 5-7 days post 
induction, centrifuged at 1500rpm 10mins and filtered through 0.45 µm filters to remove 
contaminating cells. Virus were concentrated by ultracentrifugation at 10,000g 2hrs at 4°C. 
Primary B lymphocytes were mixed with concentrated EBV at a ratio of 100 viral DNA copies 
per cell (100MOI) for bacmid-produced virus; or 30MOI for Mutu strain virus. The B cell/virus 
mixture was seeded at 0.8 million cells in 0.5ml virus per well in 48 well plates, spun down at 
1200rpm 5mins, then incubated at 37℃ for 3-4hrs. Half of the viral media was then replaced with 
fresh RPMI media. Infected cells were harvested 72hrs post infection (or the desired time points 
for time course studies), and washed with PBS to remove potentially contaminating loosely 
attached virions. 
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4.21 Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as previously described (Tempera et al., 2010) with minor 
modifications as described in (Law et al., 2010). Specifically, cells were crosslinked with 2mM of 
EGS (Thermo Pierce 21565) in PBS for 45mins, followed by 1% formaldehyde for 20mins, then 
quenched with 0.125M glycine. Pulled down DNA fragments were analyzed by real time PCR, 
primers as Table 4.6. 
	  
4.22 Immunofluorscence coupled with Fluorescent in situ Hybridization (IF-FISH) 
EBV virus infected primary B cells were harvested 72 hours post infection, and washed with 
PBS to remove loosely attached virions. Cells were then washed in PBS to a concentration of 
2.75x10^5 cells/ml, and then mounted onto slides by cytospin (Shandon Cytospin 3, Thermo 
Fisher) at 1000rpm 5mins. MTBS buffer was prepared with 4M Glycerol, 0.1M pH6.9 PIPES, 
1mM EGTA and another buffer with all the above supplemented with 0.5% Triton X-100. The two 
extraction buffers (with and without Triton X) were mixed 1:1 right before use, and used to pre-
extract cells for 2mins. Cells were fixed in 3.5% paraformaldehyde with 4mM NaOH in 1x PBS for 
7mins. Slides were then washed twice in 1x PBS, 5mins each. Blocking was done for 5mins by 
incubating slides in TK buffer of 0.1M Tris-HCl pH7.9, 1.5M NaCl, 10% BSA. 
To visualize Daxx and ATRX, indirect immunofluroscence was performed as previously 
described (Dheekollu et al., 2011). Antibodies were pre-diluted in TK buffer (anti-Daxx in 1/400 
dilution, ATRX in 1/100), then added onto slides, and incubated overnight at 37℃. Slides were 
washed 3 times in PBS the next day, then air dried 10mins. Secondary antibodies (anti-rabbit) 
were diluted in TK buffer, then added on to slides and incubated at 37℃ for 2hrs. This was 
followed by two more washes in PBS. 
103	  
	  
In preparation for subsequent FISH, a protocol previously mentioned (Chen et al., 2014) was 
slightly modified as thus. Slides were fixed in 1x PBS with 3% paraformaldehyde for 10mins, 
followed by two washed in 2xSSC, 5mins each. Then incubated in 0.1M HCl, 0.7% Triton in 1x 
PBS for 10mins on ice, followed by two 2xSSC washes of 5mins each, then air dried. DNA on the 
dried slides were denatured by placed on a 80℃ heat block for 10mins. Slides were then 
incubated in pre-warmed (77℃) hybridization buffer for 30mins, followed by two 2xSSC rinses 
and air dried. Slides were warmed up to 37℃ and incubated with FISH probe over night at 42℃. 
The FISH probe was prepared the day before use from BACmids containing the whole EBV 
genome, using a nick translation kit (Invitrogen) according to manufacturer instructions, this 
results in EBV viral genome-specific DNA probes that are conjugated to avidin. The resulting 
probes were ethanol precipitated and resuspended in hybridization buffer (Ambion). After 
hybridization (the third day), slides were washed twice with 2xSSC at 45℃ for 5mins each, then 
rinsed briefly with pre-warmed (45℃) 4xSSC with 0.1% Tween 20. Slides were then re-blocked in 
4xSSC with 5% dried milk for 5mins, then air dried. FISH-probe-targeting fluorescent secondary 
antibodies (anti-Avidin-Alexafluor 488) were diluted 1/100 in 4xSSC with 2.5% milk, mixed well 
and spundown at 12000g 4℃ for 8mins. This secondary antibody was added to slides and 
incubated for 1.5hrs at 37℃. Slides were then washed 5mins in 4xSSC with 0.1% Tween, then 
washed again 5mins in 4xSSC with 0.5mg/ml DAPI, and a last wash in 4xSSC. Salts were 
cleared out by washing in an ethanol series of 70%, 90%, and 100%, 1min each, air dried, then 
mounted with Vectasheld mounting media (Vector Laboratories). Samples were photographed 
with a Nikon E600 microscope using a 60x objective in conjunction with Image-Pro 7.0 software. 
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4.23 Figures 
 
Figure 4.1 Western blot test of BNRF1 antibodies 
Zta-reactivated 293/EBV-wt cells (WT) or 293/△BNRF1 cells complemented with FLAG-
vector (V) or FLAG-BNRF1 (B) were whole cell lysates were subject to Western blot analysis to 
test for BNRF1 antibody specificity. Purified antibodies bleed from two rabbits were tested at 
1/100, 1/500, and 1/1000 dilutions. 
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4.24 Tables 
Table 4.1 BNRF1 DID screening site directed mutagenesis primers 
Primer 
code name Sequence (5'head in caps, 3'tail in lower case) Primer name 
First set of 300aa deletion site directed mutagenesis primers 
oPL2898 
GACGATGACAAGCTTGAAGAGAGG 
gttaatgcaatagcatcatcgctg BNRF1-d1 aa 3-300 
oPL2899 
CAGCACCCCGGCCTCTTTCCCTTC 
tctccgtcttacgagttgccctgg 
BNRF1-d2 aa300-
600 
oPL2900 
GATGTGGACGAGAGCATGGACATC 
cagcggggagtgaccatcactatg 
BNRF1-d3 aa600-
900 
oPL2901 
CTGGTGGAGATGGCCCTGGCCGGG 
ctgccttgttgggtgcaaggctcg 
BNRF1-d4 aa900-
1200 
oPL2979 AGGGACTCTGCCCTGGCAGGC cacggtcgcccctccgagtg 
BNRF1-d5 aa1100-
1312 
*Only the first set of deletions were cloned using single primers 
Second set of 60aa deletion site directed mutagenesis primers 
oPL3253 CCCGGCCTCTTTCCCTTC aagggaggagagggcctac 
BNRF1-d21 aa300-
360 
oPL3303 gtaggccctctcctccctt GAAGGGAAAGAGGCCGGG BNRF1-d21 reverse 
oPL3254 GGGGTGCCGGTCGTGGCC tgcccctacgccgaaagttc 
BNRF1-d22 aa350-
410 
oPL3304 gaactttcggcgtaggggca GGCCACGACCGGCACCCC BNRF1-d22 reverse 
oPL3255 TCTCATAATGTTGGGGCCATTC aaggggggtctgctgttg 
BNRF1-d23 aa400-
460 
oPL3305 caacagcagacccccctt GAATGGCCCCAACATTATGAGA BNRF1-d23 reverse 
oPL3256 CCCCGGGCCCCAGTGCT acagtgaggcagcgaggg 
BNRF1-d24 aa450-
510 
oPL3306 ccctcgctgcctcactgt AGCACTGGGGCCCGGGG BNRF1-d24 reverse 
oPL3257 CAGTTTGTCAGCAGCTACTTC gtttccaccgccgagatg 
BNRF1-d25 aa500-
560 
oPL3307 catctcggcggtggaaac GAAGTAGCTGCTGACAAACTG BNRF1-d25 reverse 
oPL3258 CCACGGTTCCCCTCGGTGGA tctccgtcttacgagttgccc 
BNRF1-d26 aa550-
600 
oPL3308 gggcaactcgtaagacggaga TCCACCGAGGGGAACCGTGG BNRF1-d26 reverse 
Primers for cloning out Daxx interaction domain only (DID) 
oPL3561 ATGTGGACGAGAGCATGGACATC ggtcgcccctccgagtgagt 
BNRF1 d600-
1310aa F 
oPL3562 actcactcggaggggcgacc GATGTCCATGCTCTCGTCCACAT 
BNRF1 d600-
1310aa R 
Primers for adding in NLS to d26 
oPL4856 
CC ACG GTT CCC CTC GGT GGA  CTA AAG AGG CCC 
AGG AGT CCC AGT AGT  tct ccg tct tac gag ttg ccc BNRF1.d26.top.NLS 
oPL4857 
ggg caa ctc gta aga cgg agaACT ACT GGG ACT CCT 
GGG CCT CTT TAG   TCC ACC GAG GGG AAC CGT GG BNRF1.d26.bot.NLS 
*The first and second of deletions were cloned using wildtype BNRF1 as the template; while 
DID is cloned by deleting the 600aa through the C' end on the BNRF1-d1 deletion construct 
template 
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Table 4.2 HA-Daxx site directed mutagenesis primers 
5' tail 3' head ?
ATTATGCCTCCCGGGATCCTAT
G  TCTCCAAGGACCCGTGGTTCC 
Daxx-∆N(2-177aa) Fwd 
TGCTGAAAACACTGCCTCTCAG  GAGAGAAAAAAGAGAAGAGCTCG Daxx-∆HBD(178-389aa) Fwd 
CGAGCTCTTCTCTTTTTTCTCTC  CTGAGAGGCAGTGTTTTCAGCA Daxx-∆HBD(178-389aa) Rev 
GCAAGACAAAAGTGAGGAGGGC  TAGTCTAGAGGGCCCTATTCTATAG 
Daxx-∆C(390-740aa) Fwd 
*double primers are needed for site-directed mutagenesis of HBD, all the others would 
work with just one 
 
Table 4.3 BNRF1 FGARAT region site directed mutagenesis primers 
5' tail HindIII 3' head ?
GGCATCGTGCTGTCAGGG AAGCTT GTGACCTGCCTGGTGGAG BNRF1 d-PurL2 (882-889aa) 
GGATCTGAGGGAGGGAACC AAGCTT GCAGCATGTGCCCCAATC BNRF1 d-ATP (724-733aa) 
CGTGACGCTATTCTAAAGTTCCTC AAGCTT GTGGCCTTGGGGGAGCTG BNRF1 d-GATase1 (1122-1128aa) 
 
Table 4.4 GST-BNRF1 cloning primers 
????????? ?????
????????????????????????????????????? ???????? ????????????
??????????????????????????????????????????? ???????? ????????????
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Table 4.5 Reverse transcription qPCR primers 
? Sequence Name Notes 
Fwd GCC ATG GTT GTG CCA TTA CA Actin ?
Rev GGC CAG GTT CTC TTT TTA TTT CTG 
Fwd TGCCTGAACCTGTGGTTGG EBNA1 Wp/Cp initiated EBNA1 
Rev CATGATTCACACTTAAAGGAGACGG 
Fwd GCTTAGCCAGTAACCCAGCACT EBNA2 ?
Rev TGCTTAGAAGGTTGTTGGCATG 
Fwd TGCCTGAACCTGTGGTTGG EBNA3A ?
Rev GCATTCCAAGCCTGTGCCGT 
Fwd TCCAGAATTGACGGAAGAGGTT LMP1 ?
Rev GCCACCGTCTGTCATCGAA 
Fwd AAGCGGGCAGAGGAAGTATG LMP2A 
LMP2A specific 
primer used in Fig 
3.5D 
Rev AAAGAGGTAGGGCGCAACAA 
Fwd ACGACGCACACGGAAACC BZLF1 ?
Rev CTTGGCCCGGCATTTTCT 
Fwd CGGGATGACTCATCTCAACACATA LMP2 LMP2A primer used in Figure 3.5B 
Rev GGCGGTCACAACGGTACTAACT 
Fwd GATCACCACCCCCGCC gB/BALF4 ?
Rev CCTTCTTCAAAAACCCCTTCG 
Fwd ACTGCAGGTGATGTTAAATTTGTTG gp350 ?
Rev TGGAGGATGGCGAAATTTCA 
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Table 4.6 ChIP EBV genomic region primers (Fwd/Rev for each set) 
? Sequence Name Description 
Fwd TATACGAAGAAGCGGGCAGAGGAA CTCF 166 CTCF binding site close to terminal repeats 
Rev TGACCTGTTGTCCCTGAGATGTGA 
Fwd GAATGGGCGCCATTTTGTC Wp Pax5 binding site on W promoter 
Rev GGCTTATTCCTCTTTTCCCCTCTA 
Fwd GCAAGGTGCAATGTTTAGTGAGTT Zp -31 to -91nt before BZLF1 TSS 
Rev GCTGGTGCCTTGGCTTTAAAG 
Fwd AGAGTGGCTGCTACGCATTAGAG EBNA2 CTCF binding site in EBNA2 gene body 
Rev TTGGCGCTGGGTGGTT 
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5. Final Discussion 
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From what we have learned from the current literature and our own studies, we conclude 
that all gammaherpesviruses require vFGARAT homologues in the tegument to disrupt PML 
nuclear body-associated antiviral repression during early infection. By differentially modulating the 
many factors and functions associated with PML nuclear bodies, herpesviruses may have 
evolved to modulate the nuclear bodies in nuanced ways that are optimally adapted to their 
specific life cycles and preferred host cell type. Below, I discuss what we learned from this study 
in the context of  the PML-NBs and how these intrinsic antiviral resistances may be manipulated 
to aid in the establishment of EBV latent infections. 
 
5.1 PML nuclear bodies as an antiviral resistance against EBV infection 
Our studies indicate that BNRF1 breaks apart the Daxx-ATRX histone chaperone complex, 
preventing PML-associated viral gene repression.  This could be compared to how other human 
herpesviruses disrupt PML-associated antiviral resistances during early infection. HSV-1 ICP0 
degrades PML and certain isoforms of Sp100 (Chelbi-Alix and de The, 1999), leading to 
dispersion of Daxx and ATRX away from the nuclear bodies (Lukashchuk and Everett, 2010). 
HMCV pp71 disperses ATRX (Lukashchuk et al., 2008), degrades Daxx (Hwang and Kalejta, 
2007), leading to the expression of IE1 which degrades PML (Ahn and Hayward, 2000; Xu et al., 
2001). KSHV ORF75 disperses PML, Sp100, and Daxx, while degrading ATRX (Full et al., 2014). 
This comparison highlights several notable points: a) EBV BNRF1 disruption on the host is 
relatively subtle as it is the only one that has not been found to induce degradation of any PML-
associated factor (Figure 2.12). This coincides with the fact that PML-degradation by HSV-1 and 
HCMV are both in lytic infection models (fibroblasts), thus it is possible that BNRF1 non-
degradation of PML-NB components is part of the mechanism for latency establishment. b) The 
disruption targets among PML-NB components differ with virus and host cell differences, yet 
ATRX is the only PML-NB component that is consistently disrupted by all viruses studied, 
suggesting that ATRX disruption is critical for herpesvirus infection. c) The virus-induced PML-NB 
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disruption events are largely observed during early infection, supporting the notion that PML-
associated resistances are consistently active and their disruption is required for viruses to 
establish an infection. 
As discussed in previous chapters, PML is interferon-inducible and forms the structural 
scaffolding of the PML nuclear bodies; while the PML-NB components Sp100, Daxx, and ATRX 
are all associated with heterochromatin and repression of transcription. Spatially, the viral 
genomes of many DNA viruses localize to PML-NBs, including Adenovirus 5 (Ad5), Simian virus 
40 (SV40), HSV-1 and HCMV (Ahn et al., 1999; Ishov and Maul, 1996); while viral infection also 
induces increased recruitment of PML-NB constituents to these sites of viral DNA localization. 
These PML-NB components are associated with a wide variety of cellular functions including 
regulation of chromatin and transcription, DNA damage repair, post-translational protein 
modification, cell stress responses, and apoptosis (as reviewed in (Lallemand-Breitenbach and 
de Thé, 2010) ); all of these functions may potentially inhibit viral infections. Our studies of 
BNRF1 has lead us to explore BNRF1 regulation of PML-associated impacts on viral chromatin 
assembly and transcription regulation. 
Daxx has been found to be a transcription co-repressor through interaction with several 
transcription factors and heterochromatin-associated factors, while ATRX association with Daxx-
mediated gene repression has only been recently discovered. The repressive nature of Daxx and 
ATRX on viral gene expression was demonstrated with Adenovirus (Schreiner et al., 2013) and 
HCMV (Newhart et al., 2013b; Woodhall et al., 2006); while Daxx-mediated repression was 
specifically shown to be the mechanism for HCMV latency establishment in CD34+ hematopoietic 
progenitor cells. It is possible that Daxx/ATRX-mediated repression is similarly involved in latency 
establishment in gammaherpesvirus. Our observation of BNRF1 not degrading any prominent 
PML components while binding the Daxx-histone complex may be a latency establishment 
mechanism, where this vFGARAT may selectively silent lytic genes while allowing latent genes to 
express in a controlled manner. If Daxx was indeed regulated by BNRF1 to selectively repress or 
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activate viral genes, we would expect to see in the presence of BNRF1, repressive chromatic 
markers on lytic promoters and active markers on latent promoters. With the markers that we 
tested in our BNRF1-null infection ChIP, H3.3 increase and H3K4me3 decrease was detected 
throughout all regions we tested on the viral genome, with a more prominent difference on the 
first activated latent promoter Wp. However, while this is in partial support of our hypothesis, we 
could not rule out the possibility that this focus on Wp may be contributed by a difference in PCR 
primer efficiency. To rigorously test our hypothesis of BNRF1 specifically de-repressing Wp, more 
thorough testing of other potential markers is needed. Markers such as H3K9me1 and H3K9me2 
were reported to be enriched in the cellular free pool of non-nucleosomal histone H3s (Loyola et 
al., 2006); and thus prime candidates that could be tested on early infection EBV viral chromatin. 
Another related unsolved question is how BNRF1 localizes to PML-NBs. Daxx was thought 
to act as a carrier to bring HCMV pp71 into the nucleus to PML-NBs, as Daxx-knockdown 
resulted in pp71 failing to localize to nuclear bodies (Ishov et al., 2002). Daxx is also essential for 
bringing ATRX and histone (H3.3-H4) dimers to PML-NBs, suggesting that Daxx may act as a 
PML-targeting element (Delbarre et al., 2013; Ishov et al., 2004). We have noticed that Daxx-
interaction-deficient BNRF1 mutants such as d26, failed to localize to PML-NBs, while also 
showing a strong diffused signal in the cytosol (Figure 2.4). This suggests that Daxx may direct 
BNRF1 into the nucleus to PML-NBs as it does with pp71. Classic nuclear localization sites (NLS) 
could not be found on BNRF1 itself, we thus tested the hypothesis of BNRF1 being carried into 
the nucleus by Daxx. However, through sub-cellular fractionations on cells with siRNA-mediated 
Daxx knocked down, we found BNRF1 present in both cytosolic and nuclear fractions regardless 
of Daxx knockdown (Figure 5.2D). Sub-cellular fractionation studies also showed either WT or the 
d26-mutant of BNRF1 present in both cytosolic and nuclear fractions (Figure 2.5), and manually 
grafting in an NLS site in the d26 truncated region failed to increase BNRF1 nuclear entry (Figure 
5.2A and B). Thus, with current evidence, we could not prove that Daxx can bring BNRF1 into the 
nucleus. 
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In our studies we focused on the role of BNRF1 during the pre-latent phase of EBV infection 
of B-lymphocytes (Hammerschmidt and Woellmer, 2013). BNRF1 is among the most abundant 
tegument proteins in the viral particle (Johannsen et al., 2004) and its abundance decreases  
significantly by 72 hrs post-infection (Figure 3.6).  Tegument proteins are frequently involved in 
regulating the intracellular environment during early infection.  Indeed, Feederle et al. reported 
that BNRF1 is essential for viral infection of B-lymphocytes, but not essential for viral production 
in 293 cells (Feederle et al., 2006). Additionally, we found that BNRF1 had little effect on lytic 
transcription or viral DNA copy number. These findings suggest that BNRF1 is essential for early 
viral infection, but minimally important during the later stages of lytic replication. However, PML-
associated antiviral resistance is not limited to gene repression during early infection, and there 
might be other PML-associated pathways that are regulated by other viral factors. An alternative 
mechanism of PML-NB repression of viral infection has been recently reported with Varicella-
Zoster Virus (VZV) (Reichelt et al., 2012; 2011). PML-NBs of both skin and neuronal cells may 
form spherical cage-like structures that trap and sequester newly assembled nucleocapsids, 
suggesting how PML-NBs may physically impact the viral replication phase. In the case of EBV 
infection after the pre-latent phase, an early study looked specifically at the interaction between 
PML nuclear bodies and EBV infection in both latent infection and lytic replication (Bell et al., 
2000). It was found that EBV latent episomes are bound to the chromosome away from the 
nuclear bodies, with no nuclear body disruption observed. However, upon induction of lytic 
reactivation, PML-NB components including Sp100 and Daxx are rapidly dispersed away, with 
viral DNA replication starting next to the remnants of PML aggregates, and partial PML dispersion 
happening afterwards. This suggests that, like with HSV-1 and HCMV, PML-NBs are disrupted 
during EBV lytic replication. However, while these findings were done in either B cell lymphoma 
cell lines or a lymphoma-epithelial cell fusion, PML-NB disruption during latency might also 
happen in other cell types. In nasopharyngeal carcinoma (NPC) and gastric carcinoma cells, the 
latent gene EBNA1 can recruit the host kinase CK2 to phosphorylate PML, resulting in the 
degradation of PML (Sivachandran et al., 2010; 2012). It would be interesting to explore the cell 
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type differences between epithelial and B lymphocytes to understand the cause of this difference 
in EBV regulation of PML. Studies of BNRF1 in NPC cell lines such as C666 or Hone1 cells were 
considered, yet not extensively pursued in an effort to keep the scope of this project focused. It is 
thus yet unknown if BNRF1 would have different functions in the infection of epithelial cells. 
 
5.2 Regulation of Daxx, ATRX and H3.3 as a mechanism of chromatin assembly 
and latency establishment 
EBV preferentially establishes latent infections in B lymphocytes. Upon entry of the host cell, 
EBV is thought to proceed in a similar way as HSV-1 early infection; as the viral outer membrane 
fuses with cellular membranes, tegument proteins and the nuclear capsid are released into the 
cytosol. The capsid traffics to the nuclear membrane and releases the viral DNA into the nucleus. 
The viral DNA is in a linear form and devoid of histones, with the nucleic acid charges neutralized 
by polyamines (Gibson and Roizman, 1971). Upon nuclear entry, a series of events need to 
happen on the viral genome: a) shedding of polyamines, b) circularization of linear viral DNA into 
a circular episome, c) loading of histones onto viral chromatin, d) ensuring the appropriate histone 
markers on the viral chromatin for repression of lytic and activation of latent genes, and e) 
initiation of latent gene expression from the W promoter (Wp). While we don’t rule out the 
possibility of BNRF1 regulating any of these events, our observations of BNRF1 regulating Daxx-
ATRX and H3.3 suggest that the last three events are the most likely steps affected by BNRF1. 
One controversial finding in our studies is that we showed an increase in Daxx-ATRX-loaded 
H3.3 on the viral genome correlated with the repression of viral gene expression. This is in 
contrast to the majority of prior research which associates histone variant H3.3 with active 
transcription. H3.3 was first found to be enriched at actively transcribed gene bodies, poised for 
easy eviction and gene activation (Ahmad and Henikoff, 2002). As the canonical histones H3.1 
and H3.2 are loaded in a DNA-replication-coupled manner, it was thought that H3.3 acted as a 
replacement histone that could be easier to be evicted again for repeated gene expression. 
HPLC-purified H3.3 from Drosophila have been found to be enriched in active transcription-
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associated markers such as H3K4 di- and tri-methyl, H3K9 and K14 Acetylation, H3K79 dimethyl, 
and a depletion of H3K9 dimethyl (McKittrick et al., 2004). In more direct evidence, a collection of 
interferon response genes (ISGs) was found with an enrichment of H3.3 in their promoters, and 
an increase of H3.3 loading was induced in the ISG gene bodies upon ISG transactivation by 
interferon treatment. However, recent studies suggest that H3.3 is not limited to euchromatin; but 
could be associated with both active and repressive chromatin according to where and how it is 
loaded (Elsäesser et al., 2010; Szenker et al., 2011). H3.3 has recently been found to be loaded 
in heterochromatic regions such as telomeres (Goldberg et al., 2010; Wong et al., 2010), and 
pericentric DNA repeats (Drane et al., 2010). However, H3.3 loading on telomere are associated 
with transcriptional repression; while H3.3 was found to promote transcription at pericentric 
regions. Furthermore, H3.3 loading at heterochromatic regions requires Daxx-ATRX, while H3.3 
loading at active genes requires the histone chaperone HIRA (Goldberg et al., 2010). These 
studies suggest that additional modifications may be involved in H3.3 regulation of gene 
expression, and it is hard to determine if H3.3 alone dictates active or repressive chromatin. One 
possibility is that different histone chaperones load histones preloaded with different markers, and 
that genomic context and location dependent co-factors that may further modify histones after 
they are loaded. In support of this hypothesis, Elsaesser et al. found by biochemical fractionation 
of the free histone pool, that Daxx-H3.3 and HIRA-H3.3 are in two distinct populations, where 
nucleoplasmic HIRA-bound H3.3 are pre-labeled with the active marker H3K9 acetylation 
(H3K9Ac), but Daxx-bound H3.3 are free of this marker (Elsäesser and Allis, 2010). While few 
other markers were tested, this suggests that HIRA-loaded H3.3 may contain active markers that 
are absent form Daxx-loaded H3.3, providing a potential explanation to the seeming dual role of 
H3.3. 
ATRX likely plays a critical role in the regulation of viral chromatin. While BNRF1 directly 
interacts with Daxx, ATRX is the one that is detached from the complex and dispersed. In our 
infection studies in Daxx and ATRX knocked down cells, we noticed that only knock down of 
ATRX, but not Daxx, supported viral gene expression (Figure 3.5B). In recent reports of Daxx-
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ATRX chaperone of H3.3, Daxx was found to be the scaffold holding the histone protein (Elsässer 
et al., 2012; Liu et al., 2012), where Daxx contains intrinsic histone loading activity and ATRX 
targets Daxx-H3.3 to telomeric chromatin (Lewis et al., 2010). This leads to the interesting 
question of what chromatin markers or DNA sequences does ATRX target? With ATRX targeting 
telomeric and pericentric DNA repeats, Lewis et al. hypothesized that ATRX might be specifically 
targeting Daxx-H3.3 to repetitive heterochromatic regions (Lewis et al., 2010). This targeting 
specificity was further explored in other reports. Two studies showed that ATRX (utilizing the 
ADD-domain, which is distinct from the Daxx-interaction domain) recognizes heterochromatin 
with the simultaneous presence of H3K9 trimethylation and absence of H3K4 di- or tri-methylation 
(H3K9me3+, H3K4me2/3-) (Dhayalan et al., 2011; Eustermann et al., 2011); while another study 
reported ATRX targeting to G-rich tandem repeats (Law et al., 2010). EBV viral DNA during early 
infection is unlikely to contain histone markers prior to histone loading, yet the viral genome 
contains several GC-rich repetitive regions, including the terminal repeats (TR) and the W repeats, 
which constitutes the W promoter (Wp) that drives the first latent transcripts. Our finding that 
Daxx, ATRX, and H3.3 are most enriched on Wp in the absence of BNRF1 fits this model of 
ATRX targeting nicely. However, further studies are needed to look at ATRX targeting on the TRs 
as there are technical difficulties with qPCR analysis of the TRs due to its highly repetitive nature. 
With ATRX likely targeting the W repeats, there is also evidence suggesting that Daxx may 
be targeting Wp through the B-cell specific transcription factor Pax5.  Pax5 has been reported to 
form a complex with Daxx (Emelyanov et al., 2002), where Daxx may either repress or activate 
Pax5 regulated promoters. Pax5 is one of the major factors for controlling lymphocyte lineage 
development. The continuous expression of Pax5 is essential for committing hematopoetic cells 
to and maintaining a B cell lineage, as reviewed in (Ramírez et al., 2010). The presence of Pax5 
in cells thus determines their identity as B cells. As BNRF1 forms a complex with Daxx, we are 
interested in whether if BNRF1 could regulate Pax5 through Daxx-interaction. Which leads to the 
possibility that BNRF1 may act as a viral detector of host cell type, directing cell type specific 
responses such as switching between lytic and latent life cycles. Intriguingly, Pax5 binding sites 
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were found on the EBV genome, where Pax5 may activate viral gene expression driven from Wp 
(Tierney et al., 2000). A follow up study found that, EBV mutants with a deletion in the Pax5 
binding site on Wp failed to induce Wp-dependent latent gene expression upon infection of B 
cells (Tierney et al., 2007). Indeed, we have found in the analysis of multiple ChIP-seq data sets 
that Pax5 is bound to Wp, and the TRs (Arvey et al., 2012), which again matches with the GC-
rich repetitive targeting sites of ATRX. However, we have not been able to detect BNRF1 
interaction with Pax5, or even replicate the Daxx-Pax5 interaction in our IP assays. It is, though, 
possible that BNRF1 might be disrupting Daxx-Pax5 interactions, an explanation to our negative 
IP results that we have not further pursued. We were also unable to detect any evidence of 
BNRF1 affecting Wp-driven transcription, utilizing a Wp Luciferase reporter that includes the 
known Pax5 binding site. The hypothesis of BNRF1 directing latent gene expression in B cells by 
interacting with a Daxx-Pax5 complex is thus yet unproven, and may or may not be true until 
further studies were done. 
 
5.3 A general model of EBV BNRF1 as a viral defense against host resistance 
From our studies, we could build a model of how BNRF1 supports EBV early infection in B 
lymphocytes (Figure 5.1). Upon EBV entry of the host cell, BNRF1 is released into the host cell. 
BNRF1 interacts with Daxx, co-localizes with Daxx at PML nuclear bodies. BNRF1 disassembles 
the Daxx-ATRX histone chaperone complex while dispersing ATRX away from the nuclear bodies. 
This impedes Daxx-ATRX loading of histone variant H3.3 onto the viral genome, likely leading to 
an increase of the amount of histone H3.3 in the free pool, and an increase of H3K4 
trimethylation active chromatin markers. This results in BNRF1 support of viral gene expression, 
and the setup of latent infection.  
There remain many gaps in our knowledge of EBV early infection and the establishment of 
latency. Questions of interest include: What are the functions of the BNRF1 FGARAT homology 
domains, specifically the conserved domain that likely holds ADP? Does BNRF1 retain any 
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enzymatic activity? What does FGARAT have to do with PML-NB disruption? Does BNRF1 play a 
different role in B cells versus epithelial cell types? How does BNRF1 promote the presence of 
H3K4me3 markers on the viral chromatin while preventing repressive H3.3 loading? Surely much 
more needs to be learned from this fascinating topic.  Future studies on BNRF1 and other 
vFGARATs will shed light on how EBV establishes latent infection, and may provide information 
on novel approaches to inhibiting the establishment of EBV latent infections. 
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5.4 Figures 
 
Figure 5.1 Model of BNRF1 preventing H3.3 loading on viral genome by 
disassembling Daxx-ATRX 
In the absence of BNRF1 (on the left), Daxx and ATRX may load H3.3 on the EBV genome 
and repress viral gene expression. In the presence of BNRF1 (on the right), BNRF1 forms a 
complex with Daxx and histone H3.3, disassociating ATRX from the complex. This allows an 
enrichment of active H3K4me3 markers on the viral genome and allows latent gene expression. 
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Figure 5.2 Manually added NLS did not enrich BNRF1-d26 in the nucleus while 
Daxx knockdown did not prevent nuclear entry of BNRF1 
 (A) Schematic of BNRF1 mutant d26 and d26 NLS.  The NLS is derived from the EBNA1 NLS 
and contains the amino acids LKRPRSPSS (Ambinder et al., 1991).  (B) 293T cells transfected 
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with WT-BNRF1 (WT), d26, or Nuclear localization signal-tagged d26 (d26NLS) mutant were 
collected 48hrs post transfection and prepared as total cell extracts (input), cytoplasmic or 
nuclear fractions. Transfected cells fractions were assayed by Western blot with antibody to 
FLAG (BNRF1), PARP1 (nuclear marker) or αTubulin (cytoplasmic marker). (C) IP analysis of the 
BNRF1 d26NLS construct. 293T cells were transfected with WT, d26, or d26NLS, and cell lysates 
were subject to IP pulldowns with non-specific IgG and α-Daxx antibodies, then Western blots 
were probed for FLAG-tagged proteins (top panel), ATRX (middle panel), or Daxx (bottom panel). 
(D) 293T cells co-transfected with siRNA against Daxx and FLAG-BNRF1 were subject to 
subcellular fractionation and then analyzed by Western blot. 
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